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ABSTRACT 
 
Liquid-based cytology (LBC) has replaced conventional smears in the 
UK. The National Institute for Health and Clinical Excellence (NICE) 
recommended the use of LBC in 2003. ThinPrepTM (TP) and SurePathTM (SP) 
LBC systems were adopted for use in the National Health Service Cervical 
Screening Programme (NHSCSP) in the UK. NICE recommended further 
review of any other technologies or other liquid-based cytology systems in the 
future. For any second-generation LBC systems to be considered for cervical 
screening in the NHSCSP, there must be an evaluation of technical 
requirements and clinical data relating to their sensitivity, specificity and the 
percentage of inadequate samples. 
The objective of the work undertaken for this thesis was to provide 
evidence to enable an informed decision on the use of second-generation 
liquid-based cytology systems for cervical screening in the UK. The decision to 
accept the second-generation LBC system in the NHSCSP is based on its 
reliability, clinical effectiveness and cost implications. This work will determine 
the reliability, microscopic quality and reproducibility of slides of the second-
generation LBC system, and the results of this work will form the platform for 
progression to the clinical evaluation of the system. 
 Initially, four second-generation LBC systems were considered suitable 
for evaluation. They were Seroa CYTO-screen, Shandon Papspin, LGM Liqui-
PREP and CellSolution 120. However, the specifications of only one system 
(CellSolution 120TM) met NHSCSP technical requirements to start the 
evaluation. One hundred random, electronically generated colposcopy patient 
samples were used to assess the technical reliability of the CellSolution 120TM 
system. The technical evaluation consisted of pre-phase I and phase I. The 
results of these phases will decide whether the CS 120TM liquid-based cytology 
system could be carried further for clinical evaluation (phase II) or not. 
 This study was sponsored by the NHS Purchasing and Supply Agency 
(PASA), the Centre for Evidence based Purchasing (CEP) on behalf of the 
NHSCSP. The Manchester Cytology Centre (MCC) was selected as the site for 
evaluation of CellSolution 120™ and the project was managed by Guildford 
Medical Device Evaluation Centre (GMEC) on behalf of CEP. 
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1.1 Establishing the importance of the topic 
Cervical cancer is the most common cancer seen in women in 
developing countries (1). It is the twelfth most common cancer among women 
in the UK (2). The difference in the cervical cancer rate between the UK and 
developing countries is due to the introduction of computerised call and recall 
system in the “National Health Service Cervical Screening Programme” in the 
UK in 1988. Initially this screening programme, which screened all the eligible 
women in the country, was known as the National Health Service Cervical 
Screening Programme National Coordinating Network (NHSCSP NCN). Then, 
in 1994, it came to be known as the National Health Service cervical screening 
programme (NHSCSP) and later on from 1997 this cervical screening 
programme was carried out only in England, while Scotland, Wales and 
Northern Ireland initiated their own cervical screening programmes (3). The 
aim of NHSCSP is to reduce the number of women who develop and die from 
invasive cervical cancer by regularly screening women at risk so that 
precancerous changes (moderate (cervical intraepithelial neoplasia (CIN) 2) 
(22%) and severe dyskaryosis (CIN 3) (14%)) (4), which may otherwise 
develop into invasive cancer, can be identified and treated accordingly (5).  
The cervical screening programme is an expensive programme, which 
requires proper infrastructure with trained clerical staff, sample collectors, 
laboratory staff, transport system and gynaecologists to treat patients with 
abnormal cytology. Developing countries cannot afford such an expensive 
screening programme. Therefore, there is a high mortality rate of cervical 
cancer in young women worldwide (6). However, in Europe, where screening is 
much more common, the scenario is different. Six European countries started 
 21 
screening in the 1960s and ten countries or regions started at least a pilot 
programme by 2003 (7). 
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1.2 Importance of cervical screening programme 
The population screening programme in British Columbia during the 
1960s was the first to demonstrate to the world that both the incidence and 
mortality rate from cervical cancer can be reduced by implementation of a 
screening programme (8). Cervical screening has been available in the UK 
since 1967 (2). However, it was not in wide-spread use in the UK until the 
1980s. Therefore, the mortality rate from cervical cancer remained nearly the 
same till 1988 when a systematic national programme for screening women 
aged 20-64 years was introduced in this country. The programme invited 
women for screening regularly at least every 5 years (6). 
Quinn et al (9) concluded that improvement in the screening programme 
has led to a 35% fall in the incidence of invasive disease and there is a 
reduction in mortality in women under 54. The programme is believed to have 
prevented 800 deaths in 1997, but not in women over 54 (9). The incidence of 
cervical cancer has fallen sharply from 16 per 100000 in 1986 to 9.3 per 
100000 in 1997 and the mortality rate is currently falling by 7% per year  (10). 
It is estimated that 4500 lives are saved per year by the cervical screening 
programme (11). Only 413 deaths of women aged 25-64 due to cervical cancer 
were reported in England in the year 2007 (12). The cervical cancer death rate 
continues to decline by approximately 4% every year in the U.S.A (13). 
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1.3 Screening age variability across the world 
Across the world, the age group screened differs. For example, in 
Australia the age range is 18-69 years. Routine screening is carried out every 
two years. Women over 70 years who have never had a smear test, or who 
request a smear test, are also screened (14). In New Zealand regular cervical 
smear tests every three years are recommended for women from the age of 20 
till 70 if they have ever been sexually active (15). In Hong Kong, women are 
screened from 25 years to 64 years of age (16). The American Cancer Society 
recommends a woman to go for a regular cervical smear three years after 
starting sexual intercourse. It recommends a conventional smear test every 
year or a liquid-based cytology smear every two years. Women aged 30 years 
or more with three normal smears in a row can be screened every 2-3 years 
with a human papilloma virus DNA test. Women 70 years of age or older who 
have had 3 or more normal cervical smear tests in a row and no abnormal 
smear test results in the last 10 years may choose to stop having cervical 
cancer testing in America (17). 
The screening age also varies in the UK. Since 1993 in England, 
women aged 20 to 64 year have been screened regularly at three to five year 
intervals. In 2007, the policy was refined with three-yearly screening for 25-49 
year-old women and five-yearly screening for 50-64 year-old women. In 
Northern Ireland and Wales, women aged 20 to 64 years are screened 
regularly, while in Scotland women are screened from 20 to 60 years of age. 
However, studies have shown that cervical cancer is rare under the age of 25 
years and also changes in the cervix are common in younger women, which 
makes screening less cost effective in women under 25 (18). Women aged 65 
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or more are only screened if they were either not screened after the age of 50 
or have recent abnormal tests (5). 
2007-2008 statistics from the NHSCSP also show the percentage of test 
results of severe dyskaryosis or worse is highest in women aged 25-29 (1.4%), 
while it is lowest in women aged 60-64 years (0.2%) (12) (results are taken 
from GPs and community clinics) (shown in Figure 1). 
 
Figure 1: Women by age with test result severe dyskaryosis or worse as a 
percentage of all women with adequate test results 
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1.4 Method of obtaining a conventional cervical smear 
There are different methods of obtaining and processing cervical smear 
samples. In the conventional method, a woman lies down on a couch with the 
legs apart and then either a doctor or a nurse inserts a speculum to view the 
cervical os. A cervical sample is obtained using a wooden spatula or plastic 
brush. The spatula or brush is rotated twice in the clockwise direction to scrape 
the transformation zone of the cervix. The transformation zone is the area of 
cervix where the columnar epithelium is transformed to squamous epithelium 
due to vaginal acidity and the area where most abnormal changes occur. 
Therefore the transformation zone needs to be sampled in every case (19). 
The spatula or brush containing a sample is smeared on a glass slide and 
rapidly fixed with an alcohol spray to prevent the cells from degenerating. Poor 
fixation will not allow the cells to stain properly, making the smear difficult to 
assess. 
Later, the glass slides are sent along with respective request forms to 
the laboratories for Papanicolaou (Pap) staining and assessment under a 
microscope by trained staff. Dr. George Papanicolaou developed the staining 
procedure to see the cervical cells in 1930. Figure 2 below shows a stained 
conventional smear and a wooden spatula which is used to obtain the sample. 
 26 
 
Figure 2: A wooden spatula and conventional Pap smear prepared by 
spreading the cells on a slide 
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1.5 Reasons for newer method in cervical screening 
The conventional smear method results in many false negative 
diagnoses either due to sampling or screening errors. Sampling errors occur 
when all the abnormal cells may not be scraped off, abnormal cells may stick 
on the wooden spatula rather than being smeared on the slide or the cells 
transferred to the slide may not be representative of an abnormality. Screening 
errors occur if the smears are too thick, if the squamous cells are obscured by 
polymorphs, red blood cells and debris, if the screeners are tired and if there is 
difficulty in interpretation of cells. Thick smears are difficult to interpret; 
polymorphs and mucus obscure the abnormal cells and also due to drying 
artefacts. Many conventional smears were reported inadequate due to 
sampling or screening deficiences. Inadequate results raised anxiety amongst 
women and also compounded the cost per cervical sample in the National 
Health Services. Allen et al raised concerns about false negative smears in 
1996 and suggested that automated screening and human papilloma virus 
testing would lead to an improvement in the cervical screening programme 
(20). This has eventually led to a call for a change in practice in cervical 
screening but it has taken more than 10 years to implement. The US Food and 
Drug Administration approved two Liquid-based Pap tests, namely the 
ThinPrepTM in 1996 and the SurePathTM, formerly known as AutoCyte PREP or 
CytoRICH in 1999 as a replacement for the conventional smear test. The 
liquid-based Pap test involves the use of Cervex-Brush® (Rover‟s Medical 
Devices BV, Oss, The Netherlands) (shown in figure 3) or a combination of a 
plastic spatula and endocervical brush to obtain a cervical sample (sample 
from transformation zone). The head of the spatula or brush is either kept in 
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the vial containing preservative by detaching the head of the brush or removed 
after rinsing the spatula or brush thoroughly in the preservative vial. 
  
Figure 3: Cervex-Brush® used in liquid-based cervical cytology 
 
The cervical sample is automatically processed from a liquid medium in 
a laboratory, where excess mucus and polymorphs are removed and a 
representative thin layer of epithelial cells is deposited on a glass slide in a 
circle. The major differences between conventional and liquid-based slides are 
shown in table 1 below. 
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Table 1: Major differences between conventional smear and liquid-based 
slides 
Conventional smears Liquid-based slides 
Heterogeneous presentation Homogeneous presentation 
Graphic cell presentation Random cell presentation 
Variable fixation Uniform fixation 
Thick uneven groups- need 
frequent focusing 
Uniform thin layer 
Dirty background Clean background 
300-500 k cells/slide 50-70 k cells/slide 
Less nuclear detail visible More nuclear detail visible 
No residual sample Residual sample can be used for 
HPV and molecular testing 
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1.6 Efficacy of liquid-based cytology systems 
There have been various studies undertaken around the world to 
establish the efficacy of liquid-based cytology systems. The majority of 
conventional smears have now been replaced by liquid-based cytology in the 
US (21). The US Food and Drug Administration (FDA) approved the 
ThinPrepTM Pap Test as "significantly more effective" at detecting 
precancerous cervical cells (22). The US FDA also approved the SurePathTM 
Pap Test concluding that 64.4% high-grade squamous intraepithelial lesions or 
worse are detected by this testing system and it significantly reduces 
unsatisfactory samples (23). A study in Australia suggested that the 
ThinPrepTM system was also cost effective when compared to conventional 
smears (24). Bergeron recommended both the conventional smears and liquid-
based cervical cytology in Europe as he did not find any evidence suggesting 
higher accuracy of liquid-based cytology (25). In the UK, the National Institute 
for Health and Clinical Excellence (NICE) chose three laboratories, one each in 
Bristol, Norfolk and Norwich and Newcastle upon Tyne, to start a pilot study on 
liquid-based cervical cytology (LBC) in 2001. The purposes of this study were 
to determine the sensitivity of LBC, its cost effectiveness and the practical 
implications of introducing it into the NHS cervical screening programme (26). 
The laboratories at Bristol and Norfolk and Norwich used ThinPrepTM, while 
Newcastle upon Tyne used the SurePathTM liquid-based cytology system. A 
total of 100,000 routine screening cervical samples were collected, processed 
and reported.  
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1.7 National Institute for Health and Clinical Excellence (NICE) 
recommendations 
The results of the LBC pilot study were published in 2003 and showed a 
definite reduction of inadequate smears (from 9% to 1-2%), increased 
laboratory efficiency, reductions in the back-log of samples and overall cost. 
Additionally, the results showed that the sensitivity of detection of high-grade 
dyskaryosis was similar to conventional smears (27). Moreover human 
papilloma virus DNA testing and additional automation can be integrated into 
the programme with the help of liquid-based cervical cytology systems. On 
22nd October 2003, NICE recommended liquid-based cervical cytology to be 
used in National Health Service cervical screening programmes in England 
and Wales as the primary means of processing and screening cervical 
samples. NICE suggested the conversion to liquid-based cytology from 
conventional smear tests in NHS cervical screening programme within five 
years. Scotland accepted liquid-based cervical cytology as a replacement for 
conventional smear tests in April 2002. It was the first European country to 
introduce liquid-based cervical cytology (28). Slides prepared from the liquid-
based cytology methods are shown in figure 4 below. 
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Figure 4: Conventional smear (the smear throughout the slide), the ThinPrepTM 
and SurePathTM (well-circumscribed) samples  
 
NICE recommended three liquid-based cytology machines, i.e. 
SurePathTM where 48 samples are processed at a time, in 2.10 hours, the 
ThinPrepTM T2000 (semi-automated) where 1 sample can be processed in 4 
minutes and ThinPrepTM T3000 (fully automated) where 80 samples are 
processed in one cycle (2.5 hours). In the SurePathTM system, vials are 
vortexed and centrifuged by laboratory staff and then the sample is prepared 
and stained by Prep stain (a component of the SurePathTM machine). In the 
ThinPrepTM (T2000 and T3000) system, the sample is prepared by the 
machine and then stained either manually or by a separate staining machine 
using the stain of an individual laboratory (29). 
The National Institute for Health and Clinical Excellence also endorsed 
the recommendations made by companies (ThinPrepTM and SurePathTM) 
regarding a particular technique in obtaining a cervical sample for the liquid-
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based method. The central bristles of the brush should be inserted into the 
endocervical canal and the outer bristles should remain in contact with the 
ectocervix (as shown in figure 5) (30). 
 
Figure 5: The inner bristles of a brush are inserted into the endocervical canal, 
while outer bristles remain in contact with the ectocervix. (Figure adapted from 
Central Manchester and Manchester Children‟s University Hospitals, NHS 
Trust) 
 
A sample is obtained by rotating the brush inside the canal 5 times in a 
clockwise direction. This sample is either rinsed directly to remove the cells 
from the brush (by pushing the brush into the bottom of a vial at least 10 times 
and keeping the bristles apart) (ThinPrepTM) or the head of the brush 
(SurePathTM) is broken off and placed into the preservative vial (as shown in 
figure 6).  
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Figure 6: The head of the cervex brush is detached and kept into the 
preservative vial for the SurePathTM liquid-based cytology system. (Figure 
adapted from Central Manchester and Manchester Children‟s University 
Hospitals, NHS Trust) 
 
NICE also recommended a review of newer or second-generation liquid-
based cytology systems other than ThinPrepTM and SurePathTM (30). 
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1.8 Overview of ThinPrepTM and SurePathTM liquid-based cytology 
systems 
The principles of the two liquid-based cytology systems (ThinPrepTM 
and SurePathTM) are different. The ThinPrepTM system uses an ultra filtration 
method, while the SurePathTM system is based on the density gradient 
principle to obtain thin-layer circular 19mm and 13 mm smears respectively on 
the slide. The ThinPrepTM preservative vial, Cervex-Brush® and a sample are 
shown in figure 7 and the SurePathTM vial, brush and sample are shown in 
figure 8 below. 
 
Figure 7: The ThinPrepTM vial containing methanol as a preservative, Cervex-
Brush® and 19 mm circular sample on the slide 
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Figure 8: The SurePathTM vial containing ethanol as a preservative, Cervex-
Brush® and 13 mm circular sample on the slide 
  
The major differences between the two liquid-based cytology systems are 
listed in table 2 below. 
 
 
 
 
 
 
 37 
Table 2: Major differences between ThinPrepTM and SurePathTM liquid-based 
cytology systems 
ThinPrepTM SurePathTM 
Methanol as a preservative Ethanol as a preservative 
Cervex-Brush® head is rinsed in the 
vial 
Cervex-Brush® head is left in the vial 
1.9 cm diameter circle of cells 1.3 cm diameter circle of cells 
Positively charged slides are used Pre-coated slides are used 
T2000- printed barcode label is 
pasted manually  
T3000- printed barcode is 
automatically pasted on slide 
Printed barcode labels are pasted 
manually  
Individual laboratory‟s stain can be 
used, slides not stained by the 
machine 
Company‟s stain has to be used, 
slides are stained by the machine 
Any cover slip- 24x40 mm to be used Company provided cover slip 
22x50mm to be used 
Waste to be collected in Genta 
containers 
Waste is incinerated 
Residual samples can be stored for a 
shorter period (4 weeks) 
Residual samples can be stored for a 
longer period (6 months) 
Only vials to be stored Vials and test tubes to be stored 
Less space required for sample 
storage and the machine 
More space required for sample 
storage and the machine 
Cell filtration method is used Cell enrichment process is used 
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Table 2: Major differences between ThinPrepTM and SurePathTM liquid-based 
cytology systems (continued) 
ThinPrepTM SurePathTM 
T2000- labour intense 
T3000- labour free 
Labour intense process 
Well-demarcated edge- no drift Drifting of cells seen 
Holes between cells No holes between cells 
Less 3 dimensional effect seen More 3 dimensional effect seen 
Less need to use high-power Need to use high-power more often 
Metaplastic cells – a difficult area Hyper chromatic crowded cell groups- 
a difficult area 
Maximum capacity per year  
T2000- 30,000 samples 
T3000- 60,000 samples 
Maximum capacity per year 
72,000 samples 
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1.9 Troubleshooting in ThinPrepTM and SurePathTM liquid-based cytology 
systems 
No system is perfect in its application. Table 3 below shows the major 
problems in ThinPrepTM and SurePathTM liquid-based cytology systems. 
 
Table 3: Troubleshooting in ThinPrepTM and SurePathTM liquid-based cytology 
systems 
ThinPrepTM SurePathTM 
Only positively charged slides are 
required 
Pre-coating of slides if improper, 
results into either patchy or no cells  
T2000- barcode labels to be manually 
pasted on the slides 
T3000- barcode labels pasted by the 
machine 
Barcode labels to be manually pasted 
on the slides 
Lubricant artefacts are found- aqua 
gel, KY gel and powder glove 
granules are seen 
Lubricant artefacts are found- aqua 
gel, KY gel and powder glove 
granules are seen 
 Z max hole-because of too low 
vacuum tube 
 Unsecured settling chamber results 
into two rings of cells 
 Drying artefact (Chico effect) occurs 
when the settling chambers are 
removed together rather than 
individually while applying coverslip 
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Table 3: Troubleshooting in ThinPrepTM and SurePathTM liquid-based cytology 
systems (continued) 
ThinPrepTM SurePathTM 
Cells are drifted when much pressure 
is applied while coverslipping 
Cells are drifted when much pressure 
is applied while coverslipping 
Orange colour of cytoplasm is not lost Orange colour of cytoplasm is lost 
Cell crowding is less frequent Cell crowding with three 
dimensionality is seen 
Metaplastic cells versus high-grade 
and bland cell dyskaryosis are difficult 
areas to interpret 
Small atypical cells and hyper 
chromatic crowded cell groups are 
difficult to interpret 
Too cellular samples produce just a 
ring of cells and results in an 
inadequate report. However, the 
sample can be reprocessed 
 
Compression artefact occurs at the 
edges of the ring which produces 
drying artefacts- swollen cells and 
large nuclei resulting in false positive 
results 
 
Gaps (holes) between the cells are 
found 
 
Lysed blood cells can obscure the 
squamous cells 
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Table 3: Troubleshooting in ThinPrepTM and SurePathTM liquid-based cytology 
systems (continued) 
 
ThinPrepTM SurePathTM 
Hybrid capture test 2 for HPV testing 
cannot be performed if acetic acid is 
used to lyse the red blood cells 
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1.10 Cost implications per liquid-based cytology sample 
The cost per SurePathTM LBC and ThinPrepTM liquid-based cytology 
sample in a laboratory processing 60,000 samples per year is approximately 
£20.76 and £23.15 (for T2000) and £22.99 (for T3000) respectively (27). The 
summary of total costs per conventional cytology sample and LBC sample are 
shown in the table below. 
 
Table 4: Summary of total cost per conventional cytology sample and LBC 
sample: 
Items Conven- 
tional smear 
T3000 T2000 SurePathTM 
Smear taker staff 
cost 
£7.66 £4.93 £4.93 £4.93 
Administration 
cost 
£3.00 £3.00 £3.00 £3.00 
Preparation 
equipment cost 
£0.04 £0.52 £0.36 £0.22 
Preparation staff 
cost 
£0.02 £0.06 £0.41 £0.20 
Consumable cost £0.27 £4.07 £4.07 £2.00 
Smear reading 
cost 
£2.26 £1.99 £1.99 £1.99 
Other laboratory 
cost 
£8.42 £8.42 £8.42 £8.42 
TOTAL £21.68 £22.99 £23.15 £20.76 
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1.11 Highlighting a problem or controversy in the field of study 
The major problem with the current liquid-based cytology systems (i.e. 
SurePathTMand ThinPrepTM) is their cost implications. 
The National Health Service Cervical Screening Programme decided to 
explore other liquid-based cytology systems, which are at least equally or more 
efficient than the currently used LBC systems in terms of clinical and cost 
effectiveness.  
The new second-generation liquid-based cytology systems are: 
 CellSolution 120 (Synermed) 
 LiquiPrep (LGM) 
 PapSpin (Shandon)  
 Cytoscreen (Seroa) 
 Turbitec (Labonord) 
 CellSlide (Menarini) 
 MonoPrep Pap Test (MPPT) 
 MonPrep2 (MP) 
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1.12 Various studies in this field highlighting a knowledge gap in the field 
of study 
The literature search has shown published studies on this subject.  
Joonseok Park et al (31) reported that Liqui-PREPTM is more sensitive 
than conventional smears and more cost effective than ThinPrepTM and 
SurePathTM. Park et al verified Liqui-PREPTM cytology results against histology 
results. However, the authors did not mention the number of samples 
processed in one cycle and cost per Liqui-PREPTM sample. The authors also 
did not state whether an automated machine was used. Neither did they 
compare with the current liquid-based cytology systems (ThinPrepTM and 
SurePathTM). In their study none of the samples were processed by both 
techniques, namely the conventional and the Liqui-PREPTM 
Jae Soo Koh et al (32) evaluated CellPrep® (CP) liquid-based cytology 
to find a cost effective and automated alternative for cytology specimens. The 
authors in this evaluation did not avoid collection bias for the samples. They 
have compared the results of a newer liquid-based cytology system with the 
ThinPrepTM results and not with the histology results. Cell adherence and stain 
ability were problems encountered in the study.  
Cytoscreen System® (SEROA®), Turbitec® (Labonord®), CellSlide® 
(Menarini®) and Papspin® (Shandon®) are manual techniques (25). These 
liquid-based cytology techniques do not require US Food and Drug 
Administration (FDA) approval as they are not automated (25). Bergeron C et 
al (33) reported that the Cytoscreen System® (SEROA®) produced high 
quality slides and detected more squamous lesions than conventional Pap 
smears. However, only detection of atypical squamous lesions of 
undetermined significance (Borderline category in the UK, BSCC terminology) 
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was statistically significantly improved over conventional smears. Weynard B 
et al (34) stated that Papspin® (Shandon®) samples with the result of 
satisfactory, but limited by category (no equivalent terminology in the UK) had 
improvement in their presentation. Moreover, human papilloma virus test could 
be done easily on the Papspin® (Shandon®) samples. These evaluated 
techniques are compared to conventional smears rather than existing liquid-
based cytology systems and none of the systems are evaluated for diagnostic 
accuracy by comparing them with the „gold standard‟ (histology). Christian 
Garbar et al (35) evaluated the efficiency of inexpensive liquid-based cytology 
systems: Papspin® (Shandon®) and Turbitec® (Labonord®). The author 
reported that these two liquid-based cytology systems slides were similar to 
SurePathTM in reading and that cell debris, inflammatory cells, lactobacillus 
and blood were present, but they did not obscure the cells. There was no 
statistical significance between the results of both the systems. However, the 
sample size in this research was low (51 samples for Papspin® (Shandon®) 
and 215 samples for Turbitec® (Labonord®). 
NAM Jong Hee et al (36) evaluated the accuracy of a newer liquid-
based cytology system, the modified MonoPrep2 (MP) by comparing it with the 
ThinPrepTM technique. The author concluded that MP was less sensitive and 
more specific than the ThinPrepTM system. The authors also stated that the 
modified MonoPrep2 is a cost effective alternative to the currently expensive 
liquid-based cytology system. However, this is a manual technique. 
Edmund S et al (21) determined the efficacy for a newer liquid-based 
cytology system, MonoPrep Pap Test (MPPT). The authors compared the 
newer cytology results with conventional smears (10,739 split samples) and 
concluded that the newer liquid-based cytology system showed a statistically 
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significant increase in relative sensitivity and no significant difference in relative 
specificity. The newer liquid-based cytology system showed a 58% reduction in 
unsatisfactory slides. MonoPrep Pap machine is fully automated and 
processes 324 samples in 8 hours. The US Food and Drug Administration 
(FDA) approved this newer liquid-based cytology system in March 2006. 
However, the report comparing its accuracy with the conventional smear is 
only anecdotal. Data on histological and human papilloma virus test result 
correlation and cost effectiveness are still to be reviewed. Without comparison 
with the „gold standard‟ (histology), the clinical accuracy of a system cannot be 
determined. 
In summary, the published literature in this field is very limited and the 
gold standard histology outcome is not determined in the majority of the trials. 
Therefore, there is a need to carry out UK based research in order to identify 
newer, efficient, automated and a cost-effective liquid-based cytology system 
for the NHS. 
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1.13 Rationale for the present study 
There are currently only two liquid-based cytology systems approved for 
use in cervical cytology in the UK. Therefore, there is lack of competition for 
liquid-based cytology systems for cervical screening in the UK. This accounts 
for the high cost per cervical sample in the National Health Service Cervical 
Screening Programme (NHSCSP) in the UK.  
Moreover, the National Institute for Health and Clinical Excellence 
(NICE) recommended further research into the suitability of alternative slide 
processing liquid-based instruments for the detection of cervical cancer, and 
into their possible inclusion in the National Health Service Cervical Screening 
Programme (NHSCSP). In order for second-generation LBC systems to be 
introduced in the NHSCSP, they must undergo technical evaluation and 
assessment of clinical data relating to their sensitivity, specificity and the 
percentage of inadequate samples must be known (37). Although a few of the 
newer liquid based cytology systems have been evaluated, there is a lack of 
robust experimental evidence evaluating the second-generation liquid based 
cytology systems.  
Therefore, the specific aim for this research was to evaluate the second-
generation liquid-based cytology systems with the devised protocol and to 
utilise this protocol in a clinical setting. The results of this evaluation will 
provide evidence to enable an informed decision on the progression to clinical 
assessment of second-generation liquid-based cytology systems for cervical 
screening in the UK. 
This study was sponsored by the NHS Purchasing and Supply Agency 
(PASA), the Centre for Evidence based Purchasing (CEP) on behalf of the 
National Health Service Cervical Screening Programme. The Manchester 
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Cytology Centre (MCC) was selected as a site for evaluating the second-
generation liquid-based cytology systems. The project was managed by 
Guildford Medical Device Evaluation Centre (GMEC) on behalf of CEP. 
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1.14 Outline of thesis structure 
This thesis has been organised in the following way. The thesis begins 
with the materials and method, the third part shows the results, the fourth part 
deals with the discussion and the fifth part summarises the findings with 
conclusion. Finally, the references and appendices are listed.  
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MATERIALS AND METHOD 
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2.1 Materials 
Four liquid-based cytology processing systems were initially considered 
for their suitability in the National Health Service Cervical Screening 
Programme (NHSCSP). They were 
 CellSolutions Europe, CellSolution 120 
 Shandon Papspin 
 Seroa CYTO-screen 
 LGM Liqui-PREP 
The Shandon Papspin and the LGM Liqui-PREP are manual methods 
and were not considered to be suitable for preparing large numbers of samples 
in the National Health Service Cervical Screening Programme. Seroa CYTO-
screen was a semi-automated system, which is no longer available in the UK. 
The CellSolution 120TM, manufactured by Select Diagnostics, 
incorporated and supplied by Cell solutions Europe, is an automated liquid 
based cytology processor. It is computer controlled and has a potential 
throughput of 120 samples per hour. Moreover, an automated reader for this 
machine is being prepared. Therefore, CellSolution 120TM was the only product 
available in the UK, which had the potential to be included in the NHSCSP. 
This machine has been available in the UK since July 2008. A technical 
assessment of this product was performed and reliability and ease of use of 
CellSolution 120TM were determined by our project to be included in the 
NHSCSP. 
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2.2 Overview of CellSolution 120TM liquid-based cytology system 
CellSolution 120TM (Synermed) is CE (conformity mark) marked which, 
ensures that this product meets European Union consumer safety, health and 
environmental requirements. CS 120TM is an automated liquid-based cytology 
processor, which produces bar-coded slides, ready to be stained. CS 120TM is 
computer controlled. The CS 120TM slides have a thin layer of cells for visual 
evaluation either manually using a microscope, or a suitable microscopic 
imaging system unit.  
The ethanol preserved CS 120TM cervical sample is concentrated by 
centrifugation and loaded on the CS 120TM machine to produce microscope 
slides of approximately equal cellularity. The process is fully automated after 
the samples have been loaded on the machine and can achieve an optimum 
throughput of 120 samples per hour. 
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2.3 Describing different methods and rationale for choosing a particular 
method 
Different authors have used various methods to assess the accuracy of 
second-generation liquid-based cytology systems. They have either compared 
them to conventional smears, the existing liquid-based cytology systems or to 
the histology results. The split cervical samples are used for evaluation of 
newer liquid-based cytology systems.  
There has not been any standard protocol to evaluate second-
generation liquid-based cytology systems. Therefore, for this study, a protocol 
was devised to evaluate CellSolution 120TM, which was followed in a clinical 
setting. The devised protocol is shown in figure 9 below.  
 
 
  
 Not met 
 
    Technical  requirements 
acceptable Technical assessment 
                                                                     unacceptable 
 
 
 
Figure 9: Steps involved in the evaluation protocol of this trial 
 
The second-generation liquid-based cytology system, CellSolution 
120TM has not been evaluated in the UK. Therefore, this machine has to be 
Technical requirements 
(Pre-phase I) 
Review of instrument 
specifications and sample 
processing 
No further action 
of clinical 
assessment 
(Phase II) 
Technical assessment 
(Phase I) 
Assessing reliability, 
microscopic quality and 
reproducibility 
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thoroughly evaluated technically. Technical evaluation will usefully supplement 
and extend the thorough evaluation of CellSolution 120TM in this project.  
The evaluation of CellSolution 120TM was started with pre-phase I, 
where the technical requirements, namely the instrument specifications and 
sample processing were reviewed. The evaluation would be carried further to 
technical assessment (phase I) only if CellSolution 120TM satisfied the technical 
requirements (pre-phase I). Pre-phase I of the evaluation involved assessing 
the system to ensure that it met the technical requirements set out by the NHS 
Cervical Screening Programme (38) (Appendix A). The technical requirements 
(pre-phase I) to be satisfied by CellSolution 120TM liquid-based cytology 
system are shown in table 5 below. 
 
Table 5: Technical requirements (pre-phase I) to be satisfied by CellSolution 
120TM liquid-based cytology system 
No Requirements of participating 
manufacturer/ supplier 
CellSolution 120TM 
1 CE marking (IVDD 98/79/EC)  
2 Protocol acceptance 
 
 
3 Instrumentation and consumables  
4 Formal sign-off  
5 Training and customer support 
 
Table 5: Technical requirements (pre-phase 
I) to be satisfied by CellSolution 120TM 
liquid-based cytology system (continued) 
 
 
6 Instructions for use and validation 
information 
 
7 User lis   
8 Cost information  
9 Informal / formal comments  
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The technical assessment (phase I) assessed the CellSolution 120TM 
samples for their microscopic quality, reproducibility and reliability. If the 
CellSolution 120TM system does not meet or satisfy any requirements of phase 
I of the technical evaluation, there will be no further evaluation of clinical 
assessment (phase II) as it is proven that machine requirements, sample 
processing and preparation are not equivalent to the UK standard. 
This thesis deals only with pre-phase I and phase I. 
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2.4 Sample size and characteristics 
Ethical clearance was sought from National Research Ethics Services 
(NRES) prior to commencing the study. Central Manchester and Manchester 
Children‟s University Hospitals NHS trust was the sponsor for this project. 
One hundred electronically randomly assigned samples were used for 
the technical assessment (phase I) phase. Two samples were collected from 
each patient at their colposcopy visit. In order to eliminate any collection bias 
towards any of the liquid-based cytology systems (current and second-
generation), the sampling order was randomised. The nurse or doctor took the 
cervical sample in the order shown in the request form. (Request form showing 
the sampling order is shown in figure 10 below). This was done, as there is a 
possibility that the second cervical sample of either the second-generation or 
the current liquid-based cytology system may be compromised as abnormal 
cells may have been removed in the first cervical sample. 
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Figure 10: Request form showing the order of sampling to the sample taker 
 
The randomisation details were not revealed to the evaluator and other 
participants of the trial. 
The nurse smear clinic, which is part of the colposcopy clinic was also 
involved to quicken the completion of the technical assessment (phase I) 
phase. 
A small sample size (n= 100) was chosen because this phase was 
involved only in assessing the reliability, microscopic quality and reproducibility 
of CellSolution 120TM samples. Colposcopy samples were targeted for this 
evaluation, as they are treated as urgent samples, which require quick 
reporting. Therefore the results of both the liquid-based cytology systems 
(second-generation and existing) could be quickly obtained for comparison. 
Also, more varied abnormal cytology categories can be found in colposcopy 
samples than in the cervical samples sent from general practice clinics. 
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Therefore, different cytology categories could be assessed for CellSolution 
120TM in terms of their reliability and microscopic quality. Moreover, a woman 
gets time to think about taking part in the trial, as the patient information sheets 
are sent to her along with the colposcopy appointment letter. 
The samples for phase I were obtained from the colposcopy clinic at 
Salford Royal Hospital and the nurse smear and colposcopy clinic at St. Mary‟s 
Hospital, Manchester.  
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2.5 Method in detail 
The colposcopy staff at Salford Royal and St. Mary‟s Hospital, 
Manchester were informed about the project with a powerpoint presentation 
and on-going oral communication. The staff of the colposcopy clinics played a 
vital role in answering participant questions and persuading them to take part 
in this evaluation.  Patient information sheets for phase 1 (Appendix B) were 
sent to women attending these colposcopy clinics with their appointment letter. 
At the colposcopy clinics, the women were given time to consult with either a 
nurse or a doctor regarding the evaluation trial. The participant could either 
decide to take part in or opt out of the trial. If the woman decided to take part, 
she needed to sign three copies of the consent form for phase 1 (1 for the 
researcher, 1 for the patient and 1 for the patient notes) (Appendix C).  
The method of processing and evaluating CellSolution 120TM is described 
below: 
 
           A)- Pre-analytical 
1. Each request form was randomly assigned a number by a biomedical 
scientist (BMS A) prior to sample taking at colposcopy. The BMS A was 
independent of the analytical process. 
2. Two samples for each patient were received at the Manchester 
Cytology Centre: one for the current LBC system (SurePathTM or 
ThinPrepTM) and the other for CellSolution 120TM (CS 120TM) LBC 
system. 
3. After receiving the sample, the laboratory staff took a photocopy of the 
request form after hiding the randomisation label and kept the CS 120TM 
sample vial with a copy of the request form aside for the evaluator (E). 
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4.  The original form was shown to the biomedical scientist (BMS A) who 
entered the randomisation details. 
5. The evaluator (E) verified the name, NHS no, date of birth and address 
(patient details) on the request form and CS 120TM sample vial. 
6. The evaluator placed the pre printed CS 120TM barcode labels on the 
sample vial, request form and primary tube.  
7. E processed the CS 120TM primary tube and loaded it on the CS 120TM 
machine after initial homing of the machine and priming of the tubes on 
the machine. The samples were processed according to the CS 120TM 
manual. 
8. E kept a record of errors arising and how they were resolved while 
processing the samples on CS 120TM machine on the datasheet. 
9. After the prepared unstained slides were dried, E stained them manually 
(Appendix D) (initially used the autostainer for staining). 
 
B)- Analytical 
1. E prepared the datasheets and regularly sent them to CEP. E also sent 
regular maintenance sheets to CEP. The maintenance sheet is seen in 
Appendix E and datasheets are attached in Appendix F. 
2. E prepared the datasheets for error logging (for each run: error logged, 
remedial action, outcome and downtime). 
3. Quality control (for each run: start and finish time with number of 
samples processed, macroscopic assessment, repeat and supplemental 
preparations if any) was carried out by E. 
4. Screening (for each slide: macroscopic and microscopic assessment, 
which consisted of cell presentation, cytolysis, obscuring elements, 
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nuclear and cytoplasmic staining, 3 dimensionality, cell drift, cell types 
and stating dyskaryosis if any) was carried out by four individuals- 
evaluator (E), BMS B and consultant cytopathologists A & B. 
The datasheets filled by the evaluator (E) are shown in the table 6 below. 
 
Table 6: Datasheets prepared by the evaluator (E) 
Quality control 
sheet 
Error log 
sheet 
Log sheet Ergonomic 
assessment 
Sample 
processing 
Record of all 
errors and 
breakdown  
Time required 
for start and 
shut down 
Emphasis on 
ease of use 
Macroscopic 
appearance 
Actions taken 
and time 
required to 
rectify 
Maintenance Operator 
intervention 
Overall 
cellularity 
  Potential for 
human injury 
Homogeneity    
Microscopic 
appearance 
   
Repeat prep?    
 
5. Evaluator (E) entered her impression for the diagnosis of each slide on 
the excel sheet and passed the slide to the biomedical scientist (BMS 
B). 
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6. BMS B entered her results on the excel sheet and passed it to 
consultant cytopathologist A with comments regarding preparation of 
CS 120TM slides, obscuring materials if any, staining quality, adequacy 
of squamous cells and coverslipping. 
7. BMS B also entered the corresponding SurePathTM or ThinPrepTM slide 
number with their diagnosis after the CS 120TM slide was screened by 
all the team members.  
8. Consultant cytopathologist A entered her results (diagnosis with 
comments on the preparation, obscuring material, staining, adequacy 
and coverslipping) on the excel sheet and passed it to consultant 
cytopathologist B. 
9. Consultant cytopathologist B entered her results on the excel sheet 
(diagnosis with comments on the preparation, obscuring material, 
staining, adequacy and coverslipping). 
 
C)- Post-analytical 
1. The final diagnosis for each CS 120TM slide was made with the 
agreement of more than two team members‟. 
2. When there was a discrepancy between the results of team members‟, 
the result of the majority was finally recorded. 
3.  In cases (n=2) where there was no majority result between the results 
of different members of the team, the cases were reviewed by an 
independent reviewer. The diagnosis of an independent reviewer was 
taken as a verdict. 
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4. Also, in cases where there was a discrepancy between the two liquid-
based cytology systems, the cases were reviewed by an independent 
reviewer. These cases were followed up for patient management. 
5. Lastly, the CS 120TM slides were archived. 
6. After the completion of 100 samples, randomisation details were 
revealed to E to prevent any bias. 
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2.6 Cervical sampling method for CellSolution 120TM 
CellSolution 120TM is an automated newer liquid-based cytology 
system, which produces 120 bar-coded ready to be stained cytology slides in 
one run. The prepared slides have a thin layer of cells adhering to a defined 
area of the slide. The machine uses three different fluids for processing. They 
are: 
Water 
Glucyte cell adherent 
General cytology preservative 
The CellSolution 120TM machine is shown in figures 11 and 12 below. 
 
Figure 11: CellSolution 120TM machine, A- barcode scanner, B- slide tray up 
stacker, C- slide tray conveyer 
 
A 
B 
C 
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Figure 12: CellSolution 120 machine, A- loaded racks of primary tubes, B- 
discharge track, C- slide tray down stacker, D- preservative pump, E- glucyte 
pump, F- water pump, G- secondary tubes corresponding to primary tubes, H- 
computer screen (this picture is adapted from Cell Solution 120TM user 
manual) 
 
Sampling devices and method of collection of a cervical sample: 
An ethanol based preservative vial and brush (sampling devices) for CS 
120TM are shown in figure 13 below. 
A B 
C 
D 
E 
F 
G 
H 
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Figure 13: Ethanol based preservative vial and Cervex-Brush® used for 
CellSolution 120TM cervical sampling  
 
The sampling technique for CS 120TM is similar to the current liquid-
based cytology system. It is shown in figure 5 on page 33. 
The head of the brush has to be detached and left in the preservative vial. It is 
shown in figure 14 below. 
 
 
Figure 14: The head of Cervex-Brush® kept in the CS 120TM preservative vial 
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2.7 CellSolution 120TM operation process 
The process requires the CellSolution 120TM device, a centrifuge and a 
vortexer. The cervical sample is transferred to the primary tube (15 ml) from 
the preservative vial. The primary tubes are kept in the tube racks, which are 
provided by the company for centrifugation and use on the CS 120TM device. 
Firstly, the sample is centrifuged at 2150 revolutions per minute for 10 minutes. 
Then the sample is decanted, blotted and vortexed so that it can be loaded on 
the machine after initial homing. The above steps are shown in figure 15 
below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15: Some of the steps involved prior to loading samples on the CS 
120TM machine (Figure adapted from CellSolution 120TM user manual) 
 
 
Centrifugation- 1250 
rpm x 10 minutes 
Decanting 
Blotting 
Vortexing 
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The secondary tubes (5 ml) are also loaded along with the primary 
tubes on the machine. The primary tubes in the tube racks are positioned 
facing a particular way so that the barcode scanner of the machine is able to 
read their label. The positioning of primary tubes is shown in figure 16 below. 
 
 
Figure 16: The bar codes on the primary sample tubes should be orientated 
facing outward relative to the travel direction of the conveyor (Figure adapted 
from CellSolution 120TM user manual) 
  
Once the machine identifies the sample at station 1, a label 
corresponding to the primary tube is pasted on the slide by the robotic arm and 
the height of cell pellet is measured by an ultrasonic sensor at station 2. Tap 
water is added to the sample for dilution in the primary tube and glucyte is 
dispensed to the secondary tube by a set of nozzles suspended over the tubes 
at station 3. The amount of water and glucyte used in the dilution process is 
based on the number of cells in the original cell pellet. Then, at station 4, two 
disposable robotically controlled pipette tips and two pipette pumps are used to 
mix the sample multiple (10) times (an observation) with water in the primary 
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tube. After mixing, the pumps aspirate a specific volume of the cell mixture and 
transfer it to the small secondary mixing tube where glucyte has been 
dispensed. This mixture is aspirated and dispensed several times using the 
pipette tips to ensure a homogeneous mixture with glucyte. The pump 
aspirates a specific volume of the solution from the secondary tubes and the 
robotic arm transfers it to the slide. The robotic arm then disposes of the 
pipette tips into a collection container. If the device has the conservation mode 
switched on, then after dispensing the sample on the slide, the robotic arm 
preserves the remaining cytology sample into the primary tube and then 
disposes of the pipette tips.  
At station 6, the prepared slides are dried in an in-built air-drying chamber for 
forty minutes. Preservative is added to the primary tubes at station 7 to store 
the cervical sample. Later on, the slides are stained with the set-up manual 
staining system (Appendix D). Initially, the staining was done using the Leica 
Autostainer XL, but then had to shift to the manual staining system as Leica 
Autostainer XL is not the actual system, which is to be used later on with the 
CS 120TM slides. Eventually, an automated slide staining and cover slip 
machine will have to be used if the CS 120TM is approved for use in the 
NHSCSP.  
The above is an overview of the CellSolution 120TM operation process. 
The positions of the slide at different stations, primary and secondary tubes 
are clearly shown on the computer screen in figure 17 below. 
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Figure 17: Computer screen showing positions of prepared slides (A), primary 
(B) and secondary tubes (C) (Picture adapted from CellSolution 120TM user 
manual) 
 
A record of the processed samples, the amounts of water and glucyte 
used, the amount of sample transferred to the slide, the start and end times 
and errors are maintained on the computer. Moreover, these data are easy to 
retrieve and store in a memory stick. A sample record is shown in tables 7 and 
8 below. The tables are adapted from CellSolution 120TM user manual. 
 
 
 
 
 
 
A 
B 
C 
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Table 7: CellSolution 120TM operational log file 
 CellSolution 120TM Operation Log File 
 Software Rev. 1.0 
 Unit 1002  
 2008-12-17 
Date Time Process 
12/17/08 15:29:59 Program Started 
 
12/17/08  
  
15:46:16 Unit Start-up Sequence completed by 
ww 
12/17/08   
15:46:16 
Glucyte Lot No 050805, expire 
05.05.2010 
12/17/08 15:46:16 Sample Conservation Mode: ON  
 
12/17/08 15:46:16 Cellularity Adjustment: 1.0 
12/17/08 15:46:16 Preservative Addition: 1500 
12/17/08 15:49:01 Error 610-3: Ultrasonic sensor 
reading out of range  
12/17/08 16:02:35 Process Terminated 
12/17/08 16:07:38 Sample Count = 684 
 
12/17/08 16:07:38 Exit to Windows 
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Table 8: CellSolution 120TM sample log file 
CellSolution 120TM Sample Log File   
Unit 1002 
2008-12-01 
  
Scan 
Date 
Scan 
Time 
ID Pellet 
Vol 
Water Glucyte Transfer 
2008-12-
01 
09:58 
AM 
038 65.21 177.87 200.00 60.00 
2008-12-
01 
09:58 
AM 
148 51.63 140.84 200.00 60.00 
2008-12-
01 
09:59 
AM 
037 71.14 194.06 200.00 60.00 
2008-12-
01 
10:00 
AM 
036 701.27 1912.94 200.00 60.00 
2008-12-
01 
10:00 
AM 
033 94.99 259.10 200.00 60.00 
 
                                                                                                                                                                                                                                                                                                                                                      
The amount of water per sample varies between 100 and 1000ul and 
the glucyte amount is 200ul in nearly all the samples. The software of the 
machine uses an algorithm to adjust the amount of cells applied to the slide 
(cellularity) by varying the amount of water, glucyte, and transfer volumes for 
each individual sample. This dilution process is based on an approximation of 
the number of cells starting in the pelletized sample. The sample dilution 
algorithm is shown in Appendix G.   
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Different aspects of the maintenance of the CS 120TM device take place 
on a daily, weekly and semi-annual basis (Appendix E).       
                                                                                                                                                                                                    
Summary of CellSolution 120TM operating process 
Slide Handling 
Tube Handling 
Specimen Identification 
Specimen Volume Detection 
Specimen Dilution 
Specimen Mixing and Transfer 
Specimen Application to Slide 
Specimen Drying 
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2.8 Indicating problems in this evaluation 
In this complete evaluation, the major difficulty was in obtaining the 
samples. The women were not keen to take part as their sample is being 
evaluated rather than being tested on the standard system. They have a 
perception that if the machine does not pick up the abnormal cells, it will lead 
them to pain and trouble. And also since many trials requiring cervical samples 
are taking place at St. Mary‟s Hospital to make the National Health Service 
Cervical Screening Programme more robust and effective, samples were not 
easily available for this evaluation. Therefore, National Research Ethics 
Services (NRES) approval was sought in January 2009 for obtaining samples 
from the nurse smear clinic at St. Mary‟s Hospital along with the colposcopy 
samples for the completion of the technical assessment (phase I). Moreover, 
the full capacity of CellSolution 120TM liquid-based cytology system (120 
samples) was not tested. One hundred and twenty SurePathTM samples were 
run on this machine due to unavailability of CS 120TM samples. The experience 
of running 120 SurePathTM samples has been valuable.   
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3.1 Results of technical requirements (pre-phase I) of CellSolution 120TM 
liquid-based cytology system 
The results of technical requirements of CellSolution 120TM liquid-based 
cytology system are shown in table 9 below. 
 
Table 9: Results of technical requirements (pre-phase I) of CellSolution 120TM 
liquid-based cytology system 
No Requirements of participating 
manufacturer/ supplier 
CellSolution 120TM 
 
1 CE marking (IVDD 98/79/EC) √ 
2 Protocol acceptance √ 
3 Instrumentation and consumables √ 
4 Formal sign-off √ 
5 Training and customer support √ 
6 Instructions for use and validation 
information 
√ 
7 User list √ 
8 Cost information  
9 Informal/formal comments √ 
 
 
The cost of Cell Solution 120TM machine has not been disclosed to the 
team members and the participants. However, the cost can be made available 
through the distributors of CellSolution Europe after the clinical assessment 
(phase II) is completed. The remaining technical requirements of pre-phase I 
were satisfied by the CellSolution 120TM liquid-based cytology system 
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3.2 Results of technical assessment (phase I) of CellSolution 120TM 
liquid-based cytology system 
 
3.2a Ergonomic assessment results  
Operating the CellSolution 120TM device is easy. The presentation of 
the cervical samples tested on CellSolution 120TM is shown in figure 18 below.  
 
Figure 18: End result of samples processed on CellSolution 120TM machine 
 
An ergonomic assessment, which was part of the technical 
specifications verification, was carried out on the CellSolution 120TM liquid-
based cytology system. Different aspects of the operation of the instrument 
were assessed with particular emphasis on ease of use, the level of operator 
intervention and the potential for human error or injury. The observations are 
shown in table 10 below.  
 
 
 
 
Sample no. 
Date of 
processing 
A rectangular 
cervical 
smear of 
12x20 mm in 
size 
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Table 10: Results of ergonomic assessment of CellSolution 120TM liquid-based 
cytology system 
CellSolution 120TM 
operational aspects 
Ease of use Potential for human 
error or injury 
Physical access to system 
for loading samples, 
reagents, maintenance and 
trouble shooting 
Easy Need to be careful 
while loading 
samples 
General aspects of CS 120TM software use 
CellSolution 120TM 
operational aspects 
Ease of use Potential for human 
error or injury 
Loading consumables and 
reviewing on-board stock 
Easy No 
Preparing and loading 
samples 
Labour intensive, 
need to have a large 
capacity centrifuge. 
Need to have a 
specific label position 
on the primary tube, 
so that barcode 
scanner can scan 
Need to be careful 
while transferring the 
sample from the 
preservative vial to 
the primary tube 
Preparing and loading 
reagents 
Easy Need to be careful 
and insert the 
respective pump 
tubes into the 
respective reagents 
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Table 10: Results of ergonomic assessment of CellSolution 120TM liquid-based 
cytology system (continued) 
CellSolution 120TM 
operational aspects 
Ease of use Potential for human 
error or injury 
Monitoring on board 
reagent volumes and 
expiry dates 
Easy No 
Monitoring sample 
progress and expected 
completion time 
Good, though takes 
more time to dry than 
the 40 minutes, 
which is stated in the 
user manual 
No 
Sample loading and 
unloading 
Easy Need to be careful 
with the fingers while 
loading and 
unloading (there is a 
notice of caution on 
the machine) 
Sample identification Ok if primary tubes 
are placed in a 
particular direction 
No re-verification of 
label is done by the 
scanner 
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Table 10: Results of ergonomic assessment of CellSolution 120TM liquid-based 
cytology system (continued) 
CellSolution 120TM 
operational aspects 
Ease of use Potential for human 
error or injury 
Starting up and shutting 
down the instrument, time 
and instances required 
Quick While homing the 
instrument, need to 
be careful as it is 
easy to forget to pick 
up the small 
containers kept for 
collection of primed 
fluids 
Result reporting and 
reviewing, including 
printing options if not 
connected to Laboratory 
Information System 
Memory stick can be 
used to retrieve the 
data (monthly sample 
log and operational 
log) 
No 
Performing maintenance 
tasks 
Easy and well 
documented except 
for the tube buckets 
No 
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Table 10: Results of ergonomic assessment of CellSolution 120TM liquid-based 
cytology system (continued) 
CellSolution 120TM 
operational aspects 
Ease of use Potential for human 
error or injury 
Interpretation of error 
messages 
Easy to understand 
and follow the 
instructions 
No 
Quality of trouble shooting, 
information provided by the 
manufacturer 
Adequate, however, 
need to hear noise 
when an error has 
occured 
 
Sample tracking system if 
available 
Label number can be 
seen on the screen. 
The “ABCD” box, 
which gives 
information about the 
slides and their 
respective tubes is 
useful 
No 
Compatibility with slide 
stainers and coverslips if 
not included in the staining 
system  
Easy, tried on Leica 
Autostainer XL and 
Leica robotic 
coverslipper CV5030  
No 
 
Overall, the CellSolution 120TM liquid-based cytology system was 
successful in ergonomic assessment. The preparation of the samples was 
 82 
lengthy. However, after the samples have been loaded, the machine 
completed the work unless an error occurred while processing. Overall, the CS 
120TM machine was user friendly. 
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3.2b Macroscopic assessment of the slides prepared on CellSolution 
120TM liquid-based cytology system 
The CS 120TM produces a rectangular smear with an average size of 
12x20 cm. Two smears are shown in figure 19 below. 
 
Figure 19: Macroscopic appearance of the end product, rectangular smears 
(12x20 cm) produced by CellSolution 120TM liquid-based cytology system 
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3.2c Microscopic assessment of the slides prepared on CellSolution 
120TM liquid-based cytology system 
The cells look similar to those seen in the SurePathTM or ThinPrepTM 
liquid-based cytology preparations. This can be seen in the figures below, 
which show intermediate squamous cells, endometrial cells and endocervical 
cells. 
 
Figure 20:  Clumped intermediate squamous cells with nuclear grooves (60x) 
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Figure 21: Negative cytology with candida (40x) 
 
  
Figure 22: Top-hat arrangement of endometrial cells (60x)  
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Figure 23: Honeycomb sheet of endocervical cells (60x)  
 
Moreover, the dyskaryotic cells in CellSolution 120TM preparations are 
similar to those seen either in SurePathTM or ThinPrepTM preparations. 
Koilocytes, mild dyskaryosis and a hyper chromatic crowded cell group of high-
grade dyskaryosis are shown below. 
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Figure 24: Koilocytes with pencil thick cell border, clear halo beneath the cell 
membrane and nuclei with grainy nuclear chromatin (60x) 
 
 
Figure 25: A group of cells showing mild dyskaryosis where the abnormal 
nuclei are occupying more than one-third, but, less than half the total cell area 
(60x) 
Koilocytes 
Mild dyskaryosis 
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Figure 26: Hyperchromatic crowded cell group showing moderate to severe 
dyskaryosis (60x) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
High-grade 
dyskaryosis 
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3.3 Problems encountered during the evaluation of CellSolution 120TM 
liquid-based cytology system 
One hundred cervical samples were collected from colposcopy 
departments at St. Mary‟s Hospital and Salford Royal Hospital and from the 
nurse-smear clinic at St. Mary‟s Hospital for the evaluation of CellSolution 
120TM liquid-based cytology system. Two cervical samples were collected from 
each woman, i.e. one for the current liquid-based cytology system and the 
second sample for CellSolution 120TM. The evaluator (E), biomedical scientist 
(BMS B) and two consultant cytopathologists (A & B) screened CellSolution 
120TM (CS 120TM) slides. The evaluation of CS 120TM slides is documented on 
the excel sheet and datasheets.  
During the processing of the cervical samples on CellSolution 120TM, a 
few problems were observed. The manufacturer of CS 120TM was contacted 
and this resulted in certain modifications to the CS 120TM machine. The 
problems were: 
 
1. Printer:  
The robotic arm was unable to pick up some labels and paste them 
on the slides. A slide without a label is shown in figure 27 below. This was 
encountered initially, as there was no support to the label reel and the 
labels slipped off the printer head.  
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Figure 27: No label on the CS 120TM slide as the robotic arm failed to pick it up 
from the printer head 
 
2. Macroscopic quality of slides:  
Frequently, gaps were seen on the prepared slides. The figure below 
shows a gap on a smear. 
 
Figure 28: CS 120TM sample showing a big gap 
 
 
 
 
 
No label was pasted on the 
slide in spite of there being a 
corresponding sample 
The sample is washed away 
from the slide creating a gap 
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3. Microscopic quality of slides:  
Variable staining was observed. A sample with such staining is 
shown in figure 29 below. 
 
Figure 29: Variable staining on a CS 120TM slide (4x)  
 
Obscuring elements like polymorphs, bacilli and background material 
were seen on the cells, which made assessment of the CellSolution 120TM 
slides very difficult. Due to this, thirteen CS 120TM samples out of 65 samples 
(20%) were reported as inadequate, while only four SP or TP samples out of 
65 samples (6.15%) were reported as inadequate. The inadequacy rate was 
high as compared to existing liquid-based cytology systems. A comparison of 
CS 120TM samples with the SP/TP samples is shown in figure 30 below for the 
first sixty-five cervical samples. 
 92 
Comparison of CS 120 samples with SP/TP (n=65 samples)
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Figure 30: Comparison of CellSolution 120TM cervical samples with SurePathTM 
or ThinPrepTM samples  
 
Due to the high inadequacy rate, eleven CS 120TM cervical samples 
were compared with their corresponding SurePathTM or ThinPrepTM samples. 
Details on cell preservation, cytoplasm and nuclear staining, background 
material and obscuring elements were evaluated between two liquid-based 
cytology systems (current and newer) by the evaluator (E) and consultant 
cytopathologist B. The comparison is shown in table 11 below.  
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   Table 11: Comparison of CellSolution 120TM (CS 120) samples with corresponding SurePathTM (SP) / ThinPrepTM (TP) samples 
No. Sample 
No. 
CS/SP/TP 1
st
/2
nd
 
sample 
Diagnosis Cell 
preservation 
Cytoplasm 
staining 
Blue/green 
Cytoplasm 
staining 
Pink/Orange 
Nuclear 
staining 
Background 
material 
Obscuring 
A 055 CS 2
nd
 Severe 
dyskaryosis 
Poor Poor Good Acceptable Bacteria +++ +++ 
1 SP 1
st
 Borderline 
nuclear 
changes 
Good Good Good Good Bacteria ++ + 
B 056 CS 1
st
 Negative Moderate  Good Good Good Polys ++ ++ 
2 SP 2
nd
 Negative Good Good  Good Good Polys + ---- 
C 057 CS 2
nd
 Severe 
dyskaryosis 
Poor Poor Good Acceptable Bacteria & 
polys +++ 
+++ 
3 SP 1
st
 Severe 
dyskaryosis 
Good Good Good Good Bacteria & 
polys+ 
+ 
D 058 CS 2
nd
 Negative Good Poor Good Acceptable Bacteria +  --- 
4 SP 1
st
 Negative Good Good Good Good Very little --- 
E 059 CS 1
st
 Negative Poor Poor Acceptable Acceptable Bacteria +++ +++ 
5 SP 2
nd
 Negative Good Good Good Good Very little --- 
F 060 CS 1
st
 Negative Good Good Good Good Very little --- 
6 SP 2
nd
 Negative Good Acceptable Good Good Very little --- 
G 061 CS 2
nd
 Mild 
dyskaryosis 
Good Acceptable Good Acceptable Bacteria + --- 
7 SP 1
st
 Mild 
dyskaryosis 
Very good Very good Very good Good --- --- 
H 062 CS 2
nd
 Borderline 
nuclear 
changes 
Moderate Acceptable Acceptable Acceptable Bacteria & 
debris +++ 
+++ 
8 SP 1
st
        
I 063 CS 2nd Mild 
dyskaryosis 
Good Acceptable Good Acceptable Bacteria +++ +++ 
9 SP 1st Mild 
dyskaryosis 
Good Acceptable Good Good Bacteria ++ --- 
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   Table 11: Comparison of Cell Solution 120TM (CS 120) samples with corresponding SurePathTM (SP) / ThinPrepTM (TP) samples 
(continued) 
 
No. Sample No. CS/SP/TP 1
st
/2
nd
 
sample 
Diagnosis Cell 
preservation 
Cytoplasm 
staining 
Blue/green 
Cytoplasm 
staining 
Pink/Orange 
Nuclear 
staining 
Background 
material 
Obscuring 
J 064 CS 2nd Borderline 
nuclear 
changes 
Good Poor Poor Acceptable Polys + --- 
 10 SP 1st Borderline 
nuclear 
changes 
Good Acceptable Acceptable Acceptable Very little --- 
K 065 CS 1st Negative Good Good Good Good Polys +++ +++ 
 11 TP 2nd Negative Good Poor Acceptable Good Polys +  --- 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
The macroscopic and microscopic appearances of one of the 
obscured samples are shown in figure 31 and figure 32 respectively.  
 
Figure 31: Macroscopic appearance of the CS 120TM sample obscured 
by varied elements 
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Figure 32: Squamous cells are obscured by polymorphs and bacilli (20x) 
in CS 120TM sample, which resulted in an inadequate report  
 
One of the CS 120TM samples is compared with the ThinPrepTM 
sample. Their microscopy result is shown in figures 33 and 34 
respectively below. 
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Figure 33: Squamous cells are obscured by polymorphs and bacilli (20x) 
in CS 120TM sample, which resulted in an inadequate report  
 
 
Figure 34: ThinPrepTM sample corresponding to above CS 120TM 
sample showing well-dispersed and unobscured squamous cells (20x) 
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The CellSolution 120TM slides with obscured appearances such 
as those shown above were not acceptable. As a result, the CS 120TM 
liquid-based cytology system could not pass the technical assessment 
stage (phase I) of the project. To deal with this, density gradient 
centrifugation was set up to remove the excess polymorphs, bacilli and 
background material for the remaining thirty-five CS 120TM cervical 
samples of the project. The density gradient solution is added to the 
cervical sample and then the cervical sample is centrifuged at high 
speed.  
The success of the additional step (i.e. density gradient 
centrifugation) in processing CS 120TM samples is evident in the last 
thirty-five slides of the project. The staining of CS 120TM slides also 
improved with the introduction of density gradient centrifugation. Figures 
35, 36, 37 and table 12 below show this. 
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Figure 35: Squamous cells obscured with neutrophils on CS 120TM 
sample (20x) without using density gradient centrifugation  
  
Figure 36: Polymorphs and debris are removed with density gradient 
centrifugation and unobscured squamous cells are seen in the above 
CS 120TM slide (20x)  
  
Table 12: Comparison of CellSolution 120TM (CS 120) samples treated with and without density gradient centrifugation (DGC) with 
corresponding SurePathTM (SP) / ThinPrepTM (TP) samples 
No. Sample 
No. 
CS/SP/TP 1
st
/2
nd
 
sample 
Diagnosis Cell 
preserv
ation 
Cytoplasm 
staining 
Blue/green 
Cytoplasm 
staining 
Pink/Orange 
Nuclear 
staining 
Background 
material 
Obscuring 
A 
 
79 
 
CS 1
st
 BNC-Mild ok Ok -pale Ok- pale Good Polys++, 
bacilli 
+ 
79 
 
CS with DGC  Negative Holes+ 
otherwi
se fine 
Good Good Good Polys+, bacilii + 
12 
 
SP 
 
(1 blue semi-o- 
?bnc or 
multinucleated 
ec on top of 
squamous 
cells) 
2
nd
 Negative, Colp- 
NAD 
good Good Good Good Debris, 
RBCs,infl 
cells+  
Occasional 
B 80 CS 1
st
 Negative Good Good Good Good +- Debris - 
80 CS with DGC  Negative Very 
good 
Very good Very good Very 
good 
- - 
13 
 
TP 2
nd
 Negative Good Ok Very good Good - - 
C 81 CS 1
st
 BNC, koilocytes, 
ems 
Good Good Good Good +- polys  
81 CS with DGC  BNC, koilocytes, 
ems 
Very 
good 
Very good Very good Very 
good 
+- polys occasional 
14 
 
TP 2
nd
 Mild dyskaryosis. 
The follow-up smear 
was negative and 
bx was not taken 
Good Good Good (occ 
hue) 
Good +- poys, 
debris 
A few cells 
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Table 12: Comparison of CellSolution 120TM (CS 120) samples treated with and without density gradient centrifugation (DGC) with 
corresponding SurePathTM (SP) / ThinPrepTM (TP) samples (continued) 
No. Sample 
No. 
CS/SP/TP 1
st
/2
nd
 
sample 
Diagnosis Cell 
preserv
ation 
Cytoplasm 
staining 
Blue/green 
Cytoplasm 
staining 
Pink/Orange 
Nuclear 
staining 
Background 
material 
Obscuring 
D 82 CS 1
st
 Negative Good Good Good Good +- polys occasional 
82 CS with DGC  Negative Very 
good 
Very good Very good Very 
good 
occasionally - 
15 TP 2
nd
 Negative Good Overall lighter than the corresponding CS 
120 sample 
+- polys occasional 
E 83 CS 2
nd
 BNC, koilocytes 
Punch bx- wart virus 
changes 
good Good Good Good ++- bacilli, 
polys 
Few 
83 CS with DGC  BNC Very 
good 
Very good Very good Very 
good 
Polys and 
debris occ  
_ 
16 SP 
(infl/dege 
changes, 
1
st
 Negative Very 
good 
Very good  Very good Very 
good 
Polys+ - 
F 84 CS 2
nd
 Negative 
The follow-up smear 
was negative and 
bx was not taken 
Ok Good Good Good ++- polys, +- 
debris 
+ 
84 CS with DGC  Negative Good, 
halo 
Very good Very good Very 
good 
+- polys occasional 
17 TP 1
st
 Borderline Very 
good 
Very good Lighter Very 
good 
occasionally - 
G 85 CS 1
st
 Negative OK Good Good Good ++- polys + 
85 CS with DGC  Negative Very 
good 
Very good Very good Very 
good 
few - 
18 SP 2
nd
 Negative Very 
good 
Very good Good Very 
good 
- - 
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Table 12: Comparison of CellSolution 120TM (CS 120) samples treated with and without density gradient centrifugation (DGC) with 
corresponding SurePathTM (SP) / ThinPrepTM (TP) samples (continued) 
No. Sample 
No. 
CS/SP/TP 1
st
/2
nd
 
sample 
Diagnosis Cell 
preserv
ation 
Cytoplasm 
staining 
Blue/green 
Cytoplasm 
staining 
Pink/Orange 
Nuclear 
staining 
Background 
material 
Obscuring 
H 86 CS 1
st
 BNC-Mild, 
koilocytes, candida 
Good Good Good Good +- polys + 
86 CS with DGC  BNC-Mild, 
koilocytes 
Good Very good Very good Very 
good 
++- polys ++ 
19 TP 2
nd
 Mild dysk. 
The follow-up smear 
was BNC. Bx was 
not taken 
Very 
good 
Very good Very good Very 
good 
+ polys + 
I 87 CS 1
st
 Inadequate Very 
poor 
poor Good Good +++- polys, 
debris 
++ 
87 CS with DGC  Negative Good Good Good Good ++- polys, 
debris 
+ 
20 TP 2
nd
 Negative Ok Good Ok Good ++- polys, 
RBC, debris 
+ 
J 88 CS 1
st
 Negative Good Very good Good Good Occ debris - 
88 CS with DGC  Negative Very 
good 
Very good Very good Very 
good 
- - 
21 TP 2
nd
 Negative Good Overall faint staining - - 
 
 
 
 
  
The number of inadequate CellSolution 120TM samples was 
reduced after the introduction of density gradient centrifugation. The 
inadequacy rate for 100 CellSolution 120TM slides was 20%, where 
density gradient centrifugation was not used. However, the inadequacy 
rate was 5.71% after the introduction of density gradient centrifugation 
(n= 35). This is shown below in figure 37.  
Number of inadequate CS 120 samples with and 
without using density gradient centrifugation
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Figure 37: Comparison of inadequate CellSolution 120TM samples with 
and without using density gradient centrifugation 
  
 
  
4. Labels peel off from the preserved primary tubes:  
The labels on the preserved primary tubes did not stick 
properly. This is shown in figure 38 below.  
 
 
Figure 38: The primary tubes containing the preserved samples showing 
the peeling off the labels 
 
The primary tubes will need to have a different coating or better 
glue/adhesive for the labels so that they do not peel off. 
The results are discussed in the following chapter. 
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4.1 Background information 
Liquid-based cytology (LBC) has been a wonderful aid in cytology. 
The liquid-based cytology recommended by the National Institute for 
Clinical Excellence (NICE) in the UK reduced the inadequate cervical 
rate in England to 2.5% in 2008-2009 (12). Prior to the introduction of 
LBC, inadequate rates were between 9% and 10%. The NICE 
recommended the use of two liquid-based cytology systems, i.e. 
SurePathTM and ThinPrepTM because the inadequate rate reduced with 
LBC, which reduced the cost overall in National Health Service Cervical 
Screening Programme. However, the NICE did not recommend any one 
LBC system over the others. The competition for the liquid-based 
cervical cytology systems in the UK is limited to SurePathTM and 
ThinPrepTM LBC, which has led to a high price for each liquid-based 
cytology sample. Therefore, this project was started to evaluate 
CellSolution 120TM, a new liquid-based cytology system at Manchester 
Cytology Centre. The project will determine whether CS 120TM is at least 
equally or more efficient than the existing liquid-based cytology systems 
(SurePathTM and ThinPrepTM) in terms of technical and cost effectiveness 
(pre-phase I and phase I). If successful in pre-phase I and phase I, the 
new liquid-based cytology system could be clinically evaluated (phase II). 
The new liquid-based cytology system could raise competition and 
reduce the cost per cervical sample in the current economic climate if it is 
successful in clinical evaluation (phase II). 
This project was designed to provide robust and unbiased results 
in determining the technical effectiveness of the new liquid-based 
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cytology system, CellSolution 120TM. The method was divided in two 
parts: firstly, the technical requirements (pre-phase I) of the CS 120TM 
were reviewed (instrument specifications and sample processing); 
secondly, the technical assessment (phase I) of the CS 120TM machine 
(macroscopic and microscopic quality) was carried out. One hundred 
electronically randomised cervical samples were collected from two 
colposcopy clinics and the nurse smear clinic. The number of samples 
used in this project was sufficient to validate the technical qualities of the 
CellSolution 120TM machine. Split samples were not used for the study. 
Instead, two cervical samples in random order were collected from each 
woman to avoid any bias in this project. The results showed that the 
sample preparation on the CellSolution 120TM machine is better with 
integrated density gradient centrifugation. Integrated density gradient 
centrifugation was not originally described in the CellSolution 120TM 
manual.   
 
 
 
 
 
 
 
 
 
 
 108 
4.2 Primary Outcome 
This study shows that the CS 120TM system is easy to operate. 
This device produces 120 unstained slides in one run, which usually lasts 
for about two and half hours after the initial preparation. The whole 
process takes around three and half hours if carried out by a single 
individual.  
The cervical sample is collected in an ethanol based preservative 
vial. The preservative vial can be stored for two years prior to use, and 
for thirty days once a sample has been inserted. The collecting device, 
preservative vials and the end results for comparison between 
conventional smear, SurePathTM, ThinPrepTM and CellSolution 120TM 
liquid-based cytology systems are shown in figures 39 and 40 below. 
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Figure 39: The collecting device and preservative vials for conventional 
smear, SurePathTM, ThinPrepTM and CellSolution 120TM LBC systems 
  
 
Figure 40: A conventional stained smear and stained samples prepared 
with ThinPrepTM, SurePathTM and CellSolution 120TM LBC systems 
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A comparison between the three liquid-based cytology systems, 
SurePathTM, ThinPrepTM and CellSolution 120TM is shown in table 13 
below. 
 
Table 13: Comparison between SurePathTM, ThinPrepTM and 
CellSolution 120TM liquid-based cytology systems 
 
ThinPrepTM SurePathTM CellSolution 120TM 
Methanol as a 
preservative 
Ethanol as a 
preservative 
Ethanol as a 
preservative 
Cervex-Brush® head 
is rinsed in the vial 
Cervex-Brush® head 
is left in the vial 
Cervex-Brush® head 
is left in the vial  
1.9 cm diameter 
circle of cells 
1.3 cm diameter circle 
of cells 
12x20 mm rectangular 
smear 
Positively charged 
slides are used 
Pre-coated slides are 
used 
No pre-coated or 
positively charged 
slides are used 
T2000- barcode is 
manually pasted on 
slide 
T3000- barcode is 
automatically fixed 
on slide 
Barcode labels are 
manually pasted on 
the slides 
Barcode labels are 
automatically fixed 
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Table 13: Comparison between SurePathTM, ThinPrepTM and 
CellSolution 120TM liquid-based cytology systems (continued) 
 
ThinPrepTM SurePathTM CellSolution 120TM 
Individual laboratory 
stain can be used, 
slides not stained by 
the machine 
Company stain has to 
be used, slides are 
stained by the 
machine 
Individual laboratory 
stain can be used, 
slides not stained by 
the machine 
Any cover slip- 
24x40 mm to be 
used 
Company provided 
cover slip 22x50mm to 
be used 
Any cover slip can be 
used 
Waste to be 
collected in Genta 
containers 
Waste goes in regular 
sinks or incinerated 
Waste goes in regular 
sinks or incinerated 
Residual samples 
can be stored for a 
shorter period (4 
weeks) 
Residual samples can 
be stored for a longer 
period (6 months) 
Residual samples can 
be stored for a shorter 
period (4 weeks) 
Only vials to be 
stored 
Vials and test tubes to 
be stored 
Only test tubes to be 
stored 
Less space required 
 
More space required Medium space 
required 
Cell filtration method 
is used 
Cell enrichment 
process is used 
Dilution and density 
gradient centrifugation 
is used 
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Table 13: Comparison between SurePathTM, ThinPrepTM and 
CellSolution 120TM liquid-based cytology systems (continued) 
 
ThinPrepTM SurePathTM CellSolution 120TM 
T2000- labour 
intensive 
T3000- labour free 
Labour intensive 
process 
Moderately labour 
intensive, but, with 
density gradient 
centrifugation, it is 
labour intense process 
Well-demarcated 
edge- no drift 
Drifting of cells seen Drifting of cells is 
occasionally seen 
Holes between cells No holes between 
cells 
Holes between cells 
are seen in some 
cases 
Less 3 dimensional 
effect seen 
More 3 dimensional 
effect seen 
Less 3 dimensional 
effect seen 
Less need to use 
high-power 
Need to use high-
power more often 
Less need to use high-
power 
Metaplastic cells – a 
difficult area 
Hyper chromatic 
crowded groups- a 
difficult area 
A difficult area is not 
recognised yet 
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Table 13: Comparison between SurePathTM, ThinPrepTM and 
CellSolution 120TM liquid-based cytology systems (continued) 
 
ThinPrepTM SurePathTM CellSolution 120TM 
Maximum capacity 
per year  
T2000- 30,000 
samples 
T3000- 60,000 
samples 
Maximum capacity per 
year 
72,000 samples 
Maximum capacity per 
year- 62,400 samples  
if two runs/day and 
90,000 if three 
runs/day 
 
The CS 120TM system is similar to SurePathTM in terms of 
collecting the cervical sample and preservation. Also, it is similar to 
SurePathTM in preparation of the sample (density gradient centrifugation). 
However, the CS 120TM slides are to be stained separately, unlike with 
SurePathTM. Microscopically, the preparation and cells in CS 120TM look 
similar to those seen in ThinPrepTM. Therefore, it is certain that if the CS 
120TM preparations are cost and clinically effective, accepting CS 120TM 
as a newer liquid-based cytology system in NHSCSP will be easy.  
The maintenance of the CS 120TM device, data recording and 
retrieval are user friendly. The cost of the machine is unknown, however 
the cost of the reagents appears similar to SurePathTM.  The reagents 
used in the CS 120TM system are tap water, glucyte and density gradient 
solution. All the reagents are stored at 15-30 degrees celsius. Glucyte is 
a unique, non-toxic mixture of polymers, which is designed to suspend 
the cells in an isotonicaly balanced self-adhering matrix that affixes itself 
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to glass slides. It is permeable to traditional stain but does not retain the 
stain itself. However, the study shows that glucyte retains some stain and 
if the glucyte tubes are not cleaned with tap water at the end of the run, 
the pumping tubes are blocked. 
The current study found that 4.95 cells are enough per 40 high 
power field at 22x objective to label a CS 120TM slide as adequate. While, 
4.18 and 8.95 cells are required to label a ThinPrepTM and SurePathTM 
sample respectively as adequate. The calculations are recorded below 
as per the Bethesda system (39) (where 5000 cells are considered as 
adequate) in table 14. 
 
 
 
 
 
  
Table 14: Guideline for estimating cellularity of CellSolution 120TM sample (39)  
1)-number of cells required per field= 5000/area of circle/area of ocular 
 2)-diameter of an ocular or microscopic field in mm is the field number of the eyepiece/magnification of the objective 
3)-area of the field= area of circle (pi x radius2) 
 
Prep diam Area Fn20 eyepiece/10x 
objective 
Fn20 eyepiece/40x 
objective 
Fn22 eyepiece/10x 
objective 
Fn22 eyepiece/40x  
objective 
  Fields@ 
Fn20 
10X 
Cells/fields 
for 5000 
Fields@ 
Fn20 40X 
Cells/fields 
for 5000 
Fields@
fn22 
10X 
Cells/fields  
for 5000 
Fields@f
n22  
10X 
Cells/fields  
for 5000 
          
13 (SP) 132.665 42.25 118.34 676.00 7.40 34.92 143.2 558.68 8.95 
19 (TP) 283.385 90.25 55.40 1424.05 3.51 74.59 67.03 1195.71 4.18 
          
CELLSOLUTION 120 
          
15X20 (as 
stated) 
300 95.54 52.33 1528.66 3.27 78.96 63.32 1263.69 3.96 
12x20 
(normally) 
240 76.43 65.42 1222.93 4.09 63.17 79.15 1010.95 4.95 
          
 
Pi value= 3.14, FN= field number 
  
4.3 Discordant results and the reasons contributing to them 
 
 Printer- 
The robotic arm was unable to pick up some labels and paste 
them on the slides. This was initially encountered, as there was no 
support for the label reel, and the labels slipped off the printer head. 
Putting hinges onto the printer head to support the label reel solved the 
label uptake failure.  
 
 Macroscopic findings- 
Holes or gaps were found on some smears. They were thought to 
be due to: 
 Air bubbles in the glucyte line, which may result in the glucyte not 
being properly added to the sample. This results in incomplete 
fixation of the sample on the slide. 
 Incomplete drying prior to staining 
 Over vigorous washing during staining 
 Thick smears perhaps not taking sufficient glucyte 
It is possible to hypothesise that if such a gap is created on the smear 
while staining, it may result in removal of abnormal cells from that area. 
The removed area may stick to another slide and give an impression of 
abnormality in a normal smear. However, this may occur only 
infrequently as it would require some agent to enable the removed area 
of smear to stick to another slide. Nevertheless, the removal of abnormal 
cells can occur with the formation of a gap while staining.  
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 Microscopic findings- 
Variable staining was observed in a few of the stained CS 120TM 
slides. Excess polymorphs and bacilli were seen in many CS 120TM 
slides and this hindered staining. The reason for this was not clear but it 
may have something to do with the interaction between polymorphs, 
bacilli and the dyes.  
Furthermore, obscuring elements like polymorphs, bacilli and 
background material were seen on the cervical cells, which made 
assessment of the CellSolution 120TM slides very difficult. The 
CellSolution 120TM slides with such appearance were not acceptable and 
could not pass the technical assessment (phase I) of our evaluation 
project. The presence of obscuring elements resulted in a high 
inadequate rate with CellSolution 120TM as compared to the existing 
SurePath and ThinPrep liquid-based cytology systems. A high rate of 
inadequacy is usually not expected in the liquid-based cytology system 
according to the NICE guideline. The reasons contributing to cell 
obscurement in CS 120TM slides are discussed below- 
The CS 120TM device prepares the cervical sample by 
centrifugation and decanting the supernatant after centrifugation. This 
preparation step removes a little obscuring debris. The dilution of water 
and ultrasonic sensor makes adjustments in cellularity, but do not 
remove any debris. However, there is not enough barrier to remove the 
obscuring elements in CS 120TM (such as ultra filtration in ThinPrepTM 
and the cell enrichment process in SurePathTM). As a result, the 
squamous cells were frequently obscured by neutrophils and debris in 
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the CS 120TM slides. Obscured squamous cells made microscopic 
interpretation difficult. It was noted that excess polymorphs and bacilli 
even interfered with staining.  
 
 Other- 
There are certain important steps during the initial preparation of 
the cervical sample before it is loaded on CS 120TM machine. These are 
decanting and vortexing in the CS 120TM liquid-based cytology system. 
The preparations vary with different individual and also with the same 
individuals at different times if the preparation steps are not performed 
properly. Figure 41 below is shown to support the statement.  
 
Figure 41: CS 120TM sample and its repeat preparation 
 
A B 
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The same individual has prepared both the preparations. 
However, sample (A) on the left is inadequate and its repeat preparation 
on the right (B) is entirely acceptable even though it has tiny gaps. The 
obscuring elements are removed during decanting the supernatant after 
centrifugation and mixing of the cells occurs during vortexing.  
The labels do not remain adhered to the preserved primary tubes. 
This may be attributed either to the inherent quality of the tubes or the 
labels. The problem needs to be resolved because if the labels peel off 
the tubes, it will not be possible to re-process any CS 120TM sample 
when needed either for teaching or diagnostic purposes. 
The robotic pipette draws the smear from periphery to centre 
(observation) and then picks the extra sample from the centre. This 
preparation makes the peripheral part of the CS 120TM smear thinner 
than the central part. Therefore, the peripheral part of a CS 120TM slide 
dries quicker than the central part and due to its early drying, the 
peripheral part is lighter stained than the crispy and well-stained central 
part of the smear. This is shown in figure 42a and 42b below. 
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Figure 42a: Peripheral part of the CS 120TM sample (20x)   
 
 
Figure 42b: Central part of the CS 120TM sample (20x) 
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The CS 120TM liquid-based cytology system takes more time to dry 
the prepared slides than stated in the CS 120TM user manual.  
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4.4 Solutions for the discordant results  
 
 Printer- 
The introduction of hinges on the printer head to support the label 
reel made a difference in robotic uptake of labels. Consequently, label 
uptake failure was not encountered.   
 
 Macroscopic findings- 
The addition of more glucyte and a longer drying time solved the 
problem of small or tiny holes on the CS 120TM slide. The addition of 
more glucyte was tackled by increasing the number of robotic arm dips 
into the secondary tubes, which contain glucyte.  
 
 Microscopic findings- 
Density gradient centrifugation is used in the SurePathTM liquid-
based cytology system and so the concept is known to liquid-based 
cytology users. The same concept of density gradient centrifugation was 
thought of use with the CellSolution 120TM liquid-based cytology system 
by the company. However, the company was worried that during the 
decanting stage of the supernatant, scanty dyskarytotic cells may be 
removed. Therefore, density gradient centrifugation step for preparation 
of CS 120TM slides was omitted during the final development of the 
machine.  However, density gradient centrifugation step was re-
introduced by us and set up to remove excess polymorphs, bacilli and 
background material for the last thirty-five CS 120TM cervical samples of 
 124 
our project. Density gradient solution was added to the cervical sample 
and then the cervical sample was centrifuged at high speed. This 
centrifugation allowed the separation of molecules with varying weights. 
The heavy weight cells (e.g. squamous cells) settled at the bottom of the 
tubes and light weight cells (e.g. polymorphs, red blood cells, debris) 
remained at the top as the supernatant. This supernatant was then 
aspirated with a pump aspirator.  
 
Method of using density gradient centrifugation in the CellSolution 
120TM liquid-based cytology system: 
Density gradient solution was added to the cervical sample and 
centrifuged at 1100 revolutions per minute for 2 minutes. As a result, 
elements of low weight like polymorphs, red blood cells and bacilli were 
trapped above the heavy weight squamous cells. This supernatant of 
trapped debris was aspirated with an aspirator. Later on, the sample was 
centrifuged (at 2150 rpm for 10 minutes) and decanted to obtain a cell 
pellet without obscuring elements. Then the sample was vortexed so that 
it could be loaded on the CS 120TM machine after initial homing. The 
success of the additional step (i.e. density gradient centrifugation) in 
processing was evident in the last thirty-five slides of the project.  
 
Advantages of using density gradient centrifugation in the 
CellSolution 120TM liquid-based cytology system: 
 Polymorphs and debris are removed 
 The number of inadequate samples is reduced 
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 Overall cellularity remains the same 
 Staining improves as polymorphs and debris are removed 
 The dyskaryotic cells are easily recognised 
 The three dimensional effect is reduced 
The density gradient centrifugation system on the CS 120TM LBC 
system has also helped in good staining of the sample as shown in figure 
43 below.  
 
Figure 43: A- CS 120TM sample prepared without density gradient 
centrifugation, showing variable staining, B- CS 120TM sample prepared 
with density gradient centrifugation showing even staining intensity 
 
A B 
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It is thought that excess polymorphs, bacilli and background material 
make the smear thick, and this does not allow the stains to penetrate 
sufficiently. But, when the debris and background materials are removed 
with density gradient centrifugation, the smear becomes thin and allows 
an appropriate and consistent amount of stain to penetrate. 
 
Drawback of using density gradient centrifugation in CellSolution 
120TM system: 
 The process of producing slides is labour intensive and more time 
consuming. 
 
The advantages of using integrated density gradient centrifugation 
in the CellSolution 120TM liquid-based cytology system outweigh the 
drawback. Therefore, it is thus suggested that the CS 120TM device 
should integrate density gradient centrifugation as a routine process in 
preparing the cervical slides.  
 
 Other- 
Decanting and vortexing are important steps of sample 
preparation in the CellSolution 120TM liquid-based cytology system. If 
they are not performed properly, the CS 120TM sample will have many 
obscuring elements and these will make it difficult for the sample to stick 
on the slide with glucyte.   
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4.5 Unexpected outcome 
The unanticipated finding in our study was the difficulty in 
obtaining the cervical samples for this trial. Moreover, the CS 120TM 
device was not producing acceptable slides initially. However, following 
the introduction of support to the printer head and density gradient 
centrifugation, CS 120TM machine started preparing slides of an 
acceptable standard.  
With the small sample size in phase 1 of our project, caution must 
be taken, as the findings may or may not be transferable to the samples 
in clinical assessment (phase 2).  
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4.6 Comparison with the other study on the CellSolution 120TM 
liquid-based cytology system 
There is a recent study on GlucyteTM by Joel et al (40), in which 
they evaluated and compared the GlucyteTM method to both SurePathTM 
and ThinPrepTM. Joel et al used a split sample with a manual glucyte 
method. The authors concentrated the unused ThinPrep and SurePath 
samples by centrifugation, decanted them and then mixed and diluted 
them with glucyte. Later on, they applied the mixture to the slide and 
allowed it to dry into a 16-18 mm circle.  The slides were stained with 
modified Pap stain. Their study had 303 samples to show the efficiency 
of GlucyteTM. Thirty samples which were evaluated cytologically were 
compared using the Digene Hybrid Capture IITM high risk HPV assay. The 
authors concluded that the method is practical, inexpensive and easy to 
use. Their study showed equivalent sensitivity and specificity for the 
detection of squamous intraepithelial lesions when compared to both of 
the current liquid-based cytology systems. With these results, they 
supported the future value and utility of the Synermed GluCyte™ thin-
layer liquid-based cytology preparation in gynecologic applications. 
However, the authors make no statement about the quality of the slides 
prepared with GlucyteTM in their study. Therefore, it would be necessary 
to evaluate the system technically before moving on to suggest clinical 
effectiveness. Also, it is possible that the cytology samples in the study 
by Joel et al were categorised using the Bethesda classification, where 
there is a category known as “Adequate sample obscured by 
polymorphs”. There is no such category in the British Society for Clinical 
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Cytology. Therefore, our study and its results will form the basis of a 
continued evaluation of CellSolution 120TM in the clinical effectiveness 
phase (phase II) in the UK.   
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SUMMARY AND CONCLUSION 
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5.1 Summary 
The second-generation liquid-based cytology systems must 
undergo thorough evaluation to be introduced for cervical screening in 
the UK. Initially, there were four second-generation liquid-based cytology 
systems for evaluation. However, the manual methods would not serve 
large population screening and so were not evaluated any further. 
Therefore, CellSolution 120TM was the only product available in the UK at 
the time, which had the potential utility to be included in the National 
Health Services Cervical Screening Programme (NHSCSP). Full ethics 
approval was granted for the evaluation of second-generation liquid-
based cytology systems. Central Manchester and Manchester Children‟s 
University Hospitals was the sponsor of the project. This study was 
funded by the NHS Purchasing and Supply Agency, Centre for Evidence 
based Purchasing on behalf of NHSCSP. The project was managed by 
Guildford Medical Device Evaluation Centre. 
The project started with the evaluation of the CellSolution 120TM 
liquid-based cytology system in terms of technical and clinical 
effectiveness. The technical evaluation of CellSolution 120TM was divided 
into pre-phase I and phase I and these phases were dealt within this 
thesis. The colposcopy and nurse smear clinic cervical samples were 
included in the technical evaluation. The pre-phase I requirements as set 
by the NHSCSP were satisfied by the CellSolution 120TM liquid-based 
cytology system. Therefore, further evaluation (phase I) in terms of 
reliability, quality of preparation and reproducibility of one hundred 
CellSolution 120TM slides was carried out. During this evaluation, the 
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CellSolution 120TM slides initially showed polymorphs and debris 
resulting in inadequate samples. However, the CellSolution 120TM slides 
demonstrated that cell presentation was comparable to currently used 
LBC systems in the UK once a density gradient cleaning procedure was 
included at the sample preparation stage. This density gradient 
centrifugation was not listed in the CellSolution 120TM user manual. The 
density gradient centrifugation was tested on thirty-five CellSolution 
120TM samples and was shown to remove background debris and 
resulted in cleaner and more effectively stained slides. . 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.2 Conclusion 
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The protocol for evaluation of second-generation liquid-based 
cytology systems has been well laid out by the National Health Service 
Cervical Screening Programme. The protocol was divided for thorough 
evaluation of the second-generation liquid-based cytology system for 
technical and clinical components. The method of evaluation for the 
second-generation liquid-based cytology systems for the technical 
evaluation was divided into pre-phase I and phase I.  
The majority of the world literature on this subject has carried out 
the direct comparison of the new liquid-based cytology system with the 
existing liquid-based cytology systems, conventional cytology or 
histology. In our opinion, this will not serve any purpose. It will simply 
suggest whether the new liquid-based cytology system is as clinically 
effective as the existing liquid-based cytology systems or not. It will fail to 
address the practical technical issues related to the new system. The 
protocol adopted in this project evaluated the new-liquid based cytology 
system in different phases: technical requirements (pre-phase I), 
technical acceptability (phase I) and clinical effectiveness (phase II). With 
respect to technical requirements (pre-phase I), sample processing, the 
usefulness of its user manual, the training and support provided by the 
company and the cost of the machine were evaluated first. Only if these 
technical requirements (pre-phase I) laid by the NHSCSP were satisfied 
by the new liquid-based cytology system will further evaluation be carried 
out. Phase I of the protocol determines the technical parameters of the 
new liquid-based cytology system: whether the new liquid-based cytology 
system is reliable in terms of processing the cervical samples, whether it 
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is user friendly and whether it is able to reproduce the samples. 
Therefore, by adopting this protocol, there are many technical issues, 
which can be known and sorted out. The further evaluation of clinical 
effectiveness (phase II) should be carried out further only if the pre-phase 
I and phase I are satisfied by the new liquid-based cytology system to 
determine the clinical effectiveness of the new liquid-based cytology 
system in comparison to histological outcome. Overall, the adopted 
protocol evaluates the new liquid-based cytology system in detail for the 
practical introduction of the new system in the NHSCSP.  
It was through the thorough evaluation of CellSolution 120TM, that 
a new step in processing the CellSolution 120TM slides was found to be 
better than was originally described in the CellSolution 120TM user 
manual. It was concluded that the CellSolution 120™ liquid-based 
cytology system is technically competent to progress to the clinical 
assessment stage (phase II) with the introduction of density gradient 
centrifugation into the sample preparation procedure.  
 
 
 
 
 
 
 
 
5.3 Research recommendations 
 135 
A clinical assessment (phase II) of CellSolution 120TM should be 
undertaken to show the clinical effectiveness of this new liquid-based 
cytology system by direct to vial method. The clinical assessment phase 
should compare the cytology results with the histology results.  Funding 
should be sought to progress to the next stage of clinical assessment. 
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5.4 Implications for the National Health Service Cervical 
Screening Programme (NHSCSP) 
The reagents, namely water, glucyte and density gradient 
solution are used in preparing the gynaecological slides on the 
CellSolution 120TM liquid-based cytology system. Tap water can be 
used. Glucyte and the density gradient solution are easily available 
and inexpensive. The actual cost of the machine is not known to the 
researchers. A large number of CS 120TM samples (120 samples) can 
be processed in one batch. Moreover, human papilloma virus and 
molecular tests can be performed with CS 120TM sample, which can 
complement the cytology diagnosis of CS 120TM sample and also help 
in follow-up after treatment or in borderline nuclear changes. 
Considering all the above factors along with the acceptable quality of 
CS 120TM slides, the CellSolution 120TM should be further clinically 
evaluated. If the results of the clinical evaluation are acceptable, 
CellSolution 120TM can provide a cheap alternative in cervical sample 
processing in the current economic climate. 
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Appendix A 
 
NHSCSP technical requirements for LBC systems for cervical 
screening [1] 
 
1 CE marking  
All equipment and consumables, including sampling devices, 
must be CE marked with regard to the IVD Directive [2] where 
appropriate.  Any electrical device which is not an invitro 
diagnostic device must be CE marked for electrical safety [3]. 
 
2 Sample collection 
2.1 Sample collection vials 
The supplier must provide: 
 collection vials that are in regular use throughout the NHS, or 
which can be reliably and regularly supplied to the required 
quantity and quality.  It must be obvious when the vial lid is 
closed. 
 vials prefilled with collection fluid and checked for fluid loss and 
contamination 
 vial handling trays to minimise the risk of spillage. A visual 
recognition system or colour coding system is desirable.  
 vial storage requirements, including any restrictions on the 
number of vials that can be stored together and any limitations. 
 control of Substances Hazardous to Health (COSHH) 
Regulations 2002 [4] data to be available to both laboratories 
and sample takers  
 requirements and/or restrictions for the transportation of vials, 
both before and after the addition of the sample, including the 
specification of suitable transport boxes  
 advice on disposal of vials and other consumables 
 vials having a shelf life of at least 18 months from date of 
manufacture. 
2.2 Sampling devices 
 The system must use either a broom, an extended tip spatula 
or a spatula/brush combination.  The supplier must state the 
recommended device for the system and whether or not 
alternative devices can be used, and must provide reasons for 
this decision.  
 Sampling devices must be those in regular use throughout the 
NHS, or which can be supplied reliably to the required quantity.  
 The sampling device(s) must be capable of transferring an 
adequate number of cells for screening from the transformation 
zone of the cervix to the collection vial.  
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2.3 Sampling technique 
The supplier must: 
 provide detailed instructions on sampling technique and 
transfer of cells from the sampling device to the collection fluid 
 provide training for sample takers 
 highlight any differences in methodology between 
recommended sampling devices.  
3 System specifications 
The supplier must provide the following requirements: 
3.1 Physical 
 Serial number (displayed on instrument) 
 Model number (displayed on instrument) 
 Voltage, current and fusing requirements (compliant with British 
Standards) 
 Size and space required 
3.2 Utility and environmental  
 floor type and loading 
 drainage  
 water supply 
 electrical supply  
 an uninterrupted power supply and electrical filter if required 
 waste disposal 
 a system capable of operating between 15–35°C and under 
typical laboratory humidity 
4 Installation and commissioning 
The supplier must: 
 install the equipment using their own service engineers or 
appointed agent 
 provide advice and support if the instrument has to be moved 
after installation 
 state the assistance and support to be provided during the 
commissioning phase, acceptance testing and validation of 
performance  
 satisfactorily demonstrate that the equipment is working within 
specification before formal handover.  
5 System operation 
The system must be easy to operate and routinely maintained by 
laboratory staff (biomedical scientists and/or medical laboratory 
assistants). 
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5.1 Instructions for use (IFU) 
The supplier must provide a comprehensive operator manual in 
English which includes: 
 start-up  
 calibration  
 sample processing  
 decontamination   
 fault recognition and troubleshooting 
 system features that minimise the risk of carry-over between 
specimens 
 waste disposal.  
5.2 Throughput 
 Start-up and shut-down (including decontamination procedures) 
should not take longer than 15 min per day.  Ideally, the system 
should be capable of running directly from standby. 
 Any system must be automated to a degree that comfortably 
permits the processing of 20 sample vials per hour by a single 
operator (not including staining).  
 The throughput of the system for slide production, staining (if 
included) and cover slipping (if included) should be provided.  
 The supplier must make it clear which processes are included 
in their system. 
5.3 Maintenance 
The in-house maintenance procedures must be documented in 
the instructions for use, together with an estimate of the time 
required. 
 
5.4 Error notification and troubleshooting 
The system should provide messages that identify common 
errors to operators.  Corrective actions must be documented in 
the instructions for use. 
 
5.5 Consumables 
 Working reagents must be supplied ready for use or be simple 
to prepare.  
 Reagents should be stable on board the system for at least 
three days. 
 The shelf life of the reagents should be at least three months 
upon delivery.  
 All consumables must be readily available from the suppliers as 
stock items. 
 Glass slides that are compatible with the system must be 
specified or supplied.  
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6 Manufacturer/supplier services 
6.1 Training 
The supplier must provide full training in English which includes: 
 system operation 
 maintenance 
 quality control 
 waste disposal 
 Sufficient slides, covering all diagnostic categories used in the 
UK, must be provided in accordance with the NHSCSP 
publication Liquid Based Cervical Cytopathology Training log 
[5].  
6.2 Engineering and technical support 
The supplier must specify or provide: 
 the external service requirements and contracts available, 
together with guaranteed response times and level of support 
outside normal working hours 
 specific exclusions to the contract 
 options for back-up/loan systems must be available should 
long-term down-time occur (two weeks or more) 
 an English speaking point of contact 
 all service reports and data relating to routine performance, 
planned and unplanned maintenance, and fault rectification. 
7 Slide preparation 
7.1 Specimen preparation 
The system process must:  
 be suitable for use with all cervical cytology samples, including 
those which are heavily blood-stained or mucoid  
 have the capability to remove a significant number of 
polymorphs, blood and mucus  
 produce slides that are a representative sample of the epithelial 
cell content of the original sample  
 allow additional slides of equivalent content to be produced 
from the original sample (for training and quality assurance 
purposes) 
 spread cells evenly on the slide for ease of screening 
 hold cells in position so that they do not move once the cover 
slip has been applied  
 produce LBC preparations which are similar to each other when 
taken from women of the same age  
 produce inadequate test rates within the 10th to 90th centile of 
performance in current LBC laboratories in England  
 achieve a high and low grade pick up rate within the 10th to 
90th centile of performance in current LBC laboratories in 
England; this should be demonstrated in both split sample and 
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direct to vial studies in various asymptomatic populations, 
similar to that of the UK, and published in peer review journals 
or provided for peer review by the NHS. 
7.2 Staining procedure 
 The prepared slides must be compatible with NHSCSP 
approved staining regimes. 
 If slide staining forms part of the system, it must produce cell 
preparations that meet the standards for liquid based cytology 
[6].  
 The slide and associated slide carriage devices should be 
suitable for use with automated staining and/or automated 
cover slipping devices if this is not part of the system. 
7.3 Labelling  
 The vials must carry preprinted labels for documenting patient 
demographics which conform to UK standards.  There must be 
sufficient space to enter patient details and enable indelible 
marking with ballpoint pens.  
 Systems that generate slide labels must ensure that these 
always match those for the relevant vial.  
 If bar code labels are used, the supplier must be able to provide 
a system that is compatible with UK systems of labelling, or 
recommend such a system that is available in the UK.  
7.4 Quality control  
 The reject rate for both single and multisample processors must 
be less than 2%.  
 Calibration and quality control (QC) procedures must be stated. 
 The system must provide QC and calibration data.  
 The QC results should be clearly indicated with appropriate 
status flags and should be available for long-term storage for 
accreditation compliance.  
8 Health and safety  
The supplier must: 
 confirm compliance of the system with relevant regulations for 
electrical, mechanical and biological safety  
 for all reagents, confirm compliance with relevant regulations 
regarding shipping, labelling and information on hazardous 
substances.  COSHH product data sheets and risk 
management information must be provided  
 provide a decontamination protocol for the system with 
recommendations as to when it should be used 
 provide recommendations for handling and disposal of „high 
risk‟ samples  
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 comply with all UK and EC safety regulations and any guidance 
issued by the Medicines and Healthcare products Regulatory 
Agency (MHRA)  
 ensure that the system does not generate dangerous aerosols. 
8.1 HAZMAT  
 Vial preservative solutions must inactivate viruses that model 
relevant human pathogens such as human immunodeficiency 
virus type 1 (HIV-1), hepatitis B virus (HBV) and hepatitis C 
virus (HCV). As it is not possible to culture HBV and HCV in 
vitro, models for these viruses which have similar 
physicochemical properties must be used.  
 Material safety data (MSD) sheets or comprehensive operator 
manuals must provide information on the following: packaging, 
chemical composition, storage requirements, stability, 
handling/disposal and any interfering substances.  
9 Sample transportation  
 The screening procedure must include a means of sample 
transportation.  Details of postal approval must be provided. 
 The supplier must provide details of a sample tracking system if 
it is available. 
10 Additional requirements 
The system should be compatible with requirements for 
additional tests (e.g. human papillomavirus testing) that may 
need to be performed on the same sample.  
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Appendix B 
 
Patient information sheet 
 
 
Participant Information Sheet Phase 1 Version 1   
    REC 07/H1003/109 
 
 
PARTICIPANT INFORMATION SHEET  
Evaluation of the potential of second generation Liquid Based 
Cytology (LBC) techniques for detection of cervical abnormality  
Invitation to participate 
We would like to invite you to take part in a research study conducted by 
the Manchester Cytology Centre (MCC).  Before you decide whether or 
not to participate, it is important for you to understand the reasons for the 
study and what it would involve for you. Please take time to read this 
leaflet and discuss it with family and friends or your own doctor if you 
wish. You will also be able to talk to the colposcopist or nurse practitioner 
on your appointment date about the study and clarify any doubts. 
In the meantime if you would like more information please call our 
independent programme coordinator Mrs Janet Marshall on 0161-276-
5103 
 
The leaflet is divided into two (2) parts: 
 Part 1 explains the purpose of the research and what will happen 
if you take part 
 Part 2 provides information on data protection and research 
conduct  
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Participant Information Sheet Phase 1 Version 1   
    REC 07/H1003/109 
 
 
PART 1  
 
What is the purpose of the study?  
The aim of the study is to compare the performance of a new cervical 
sampling and processing system to that of an established NHS approved 
one.   
 
Why have I been invited?  
You have been invited because you are due to have an examination at 
colposcopy clinic where routinely you will have a cervical smear test 
done.  
 
Do I have to take part? 
It is up to you to decide. We will describe the study as we go through this 
information sheet and if you do decide to take part we will ask you to sign 
a consent form to show you fully understand the study and you are in 
agreement. You are free to withdraw at any time, without giving a reason 
and this in no way will affect your standard care. 
 
What is being tested? 
New sampling and processing systems, 2nd Generation Liquid Based 
Cytology (LBC), with which to take and prepare cervical samples are 
being tested. Currently in England and Wales there are two systems 
which have been tested and approved by the NHS Cervical Screening 
Programme. For any other methods to be approved there must be 
evidence to show that its performance meets the standards of these 
systems in terms of clinical usefulness, value for money and acceptance 
by patients. In this the first phase of the study, the 2nd Generation LBC 
technology will be assessed against the performance of one that is NHS 
approved, either ThinPrep or SurePath. 
 
What will happen to me if I take part?  
When you come to colposcopy clinic on your appointment day, the 
colposcopist or nurse practitioner will go through the study again with you 
and answer any questions you may have. If you do agree to take part 
you will then have an examination and two cervical samples will be 
taken: one with the NHS approved device, ThinPrep or SurePath and the 
other with that of the 2nd Generation LBC technology. The order by which 
the samples will be taken will be random. Both samples will be sent to 
the Manchester Cytology Centre where assessment will be done and the 
two methods will be compared. 
The time required to have the second sample will be approximately 
twenty (20) seconds. 
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What do I have to do? 
You do not have to do anything different and there are no lifestyle, 
medical health product or dietary restrictions. 
 
What are the possible disadvantages and risks of taking part? 
Taking a second cervical sample will result in your colposcopy 
examination lasting approximately twenty seconds more but there should 
be no additional discomfort. Neither will your health be at risk. 
 
What are the possible benefits of taking part? 
There are no potential benefits.  
 
What happens when the research study stops? 
On completion of this phase of the study, the results will be assessed 
and if the 2nd Generation LBC system compares favourably with the NHS 
approved method then phase 2 will take place on another patient 
population. 
 
Will I be paid? 
No payment will be made 
 
Will my taking part be kept confidential? 
Yes. We will follow ethical and legal practice and all information will be 
handled in confidence. All information will be handled in adherence to the 
Data Protection Act (1998) and Trust Confidentiality policies 
 
 
 
 
End of Part 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
If the information in Part 1 has interested you and you are considering 
participation, please read the additional information in Part 2 before 
making any decision. 
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Participant Information Sheet Phase 1 Version 1   
    REC 07/H1003/109 
 
 
PART 2  
 
What if relevant new information becomes available? 
Sometimes we get new information about devices and tests being 
studied. If this happens, the colposcopist or nurse practitioner will tell you 
and discuss whether you should take part in the study. 
If at the end of this phase we do not have a favourable performance 
indicator of the 2nd Generation technology then we will not proceed to 
phase 2. 
 
What will happen if I don’t want to carry on? 
This phase of the study requires one extra sample to be taken at your 
colposcopy visit. You are free to decline participation and we would like 
to assure you that your standard treatment will in no way be affected. 
 
What if there is a problem? 
Every effort will be made to ensure you fully understand the study and all 
your concerns addressed during this time. We do not believe you will 
suffer any harm by participating; however, if you have any complaint 
about the way you have been dealt with please contact our independent 
programme coordinator Mrs Janet Marshall on 0161-276-5103. If you 
remain unhappy and wish to complain formally, you can do this through 
the NHS complaints procedure.  
 
What will happen to any samples I give? 
At the laboratory both samples will be prepared and processed onto 
glass slides for interpretation by technical and medical staff. In 
accordance with the Human Tissue Act and the Royal College of 
Pathologist recommendations, any unused material will be ethically and 
confidentially disposed after assessment. The slides will be stored for ten 
years in accordance with the aforementioned recommendations and after 
such time, these too will be disposed in the same ethical and confidential 
manner.  
 
What will happen to the results of the study? 
On completion of the study a written report will be made to the Centre for 
Evidence Based Purchasing, the commissioners of the study. This report 
will be available online. 
 
Who is organising and funding the research? 
The study is organised by the Manchester Cytology Centre under the 
Guidance of the guidance of Central Manchester and Manchester 
Children‟s University Hospitals NHS trust, whilst funding has been 
provided by the Centre for Evidence Based Purchasing who 
commissioned the study. 
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Who has reviewed the study? 
All research in the NHS is looked at by an independent group of people, 
called a Research Ethics Committee to protect your safety, rights, 
wellbeing and dignity. This study has been reviewed and given 
favourable opinion by the South Manchester Research Ethics Committee 
 
End of Part 2 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Thank you for taking the time to read this leaflet. If you have any questions 
please call our independent programme coordinator Mrs Janet Marshall on 
0161-276-5103. 
At colposcopy you will also have a chance to discuss the study and decide 
if you would like to take part.  
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Appendix C 
Consent form  
  
Study Number: REC 07/H1003/109 
Phase: 1 
Patient Identification Number for this Trial: 
CONSENT FORM  
Title of Project: Evaluation of the potential of second generation Liquid 
Based Cytology (LBC) techniques for detection of cervical abnormality in 
a high prevalence setting of colposcopy. 
 
Name of Lead Researcher: Dr. Minaxi Desai 
Please read carefully and initial boxes if in agreement 
          
                    Participant 
          
                             Initials 
1) I confirm I have received in advance, read and understood 
the Patient Information Sheet (Version 1) for the above study and 
have had the opportunity to ask questions. 
 
2) I understand that my participation is voluntary and that I am free 
to withdraw at any time, without giving any reason, without my 
medical care or legal rights being affected. 
 
3) I understand that during this study I would have two (2) cervical 
samples taken, one using an NHS approved sampling device, 
SurePath or ThinPrep and the other using that of a 2nd 
Generation LBC Technology. 
 
4) I understand the order by which the smears are taken will be 
random     
  
5) I understand that sections of my cervical screening records may 
be looked at by responsible individuals from the Manchester 
Cytology Centre and only where it is relevant to this study. 
 
 
6) I agree to take part in this study 
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__________________        _______________            ______________ 
Name of Patient  Date     Signature  
 
 
__________________ _________________        ______________ 
Name of consent taker Date    Signature 
 
_______________________ 
Designation 
 
 
1 for patient; 1 for researcher, 1 for patient‟s notes 
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Appendix D 
Manual staining system 
 
The steps involved in this staining method are shown in the table 11 
below. 
Table 11: Staining steps involved for Cell Solution 120 samples 
Step No. Reagent Time 
1 Tap water 1:00 
2 Gill‟s haematoxylin 4:00 
3 Tap water 10 dips  
4 Tap water 10 dips 
5  95% alcohol 10 dips 
6 95% alcohol 10 dips 
7 OG-6 0:30 
8 95% alcohol 10 dips 
9 95% alcohol 10 dips 
10 EA-50 6:00 
11 95% alcohol 10 dips 
12 95% alcohol 10 dips 
13  100% alcohol 10 dips 
14  100% alcohol 10 dips 
15  100% alcohol 10 dips 
16 Xylene 1:00 
17 Xylene 1:00 
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Appendix E 
 
Maintenance sheet for CellSolution 120TM  
 
 
 158 
Appendix F 
 
Data sheets- CEP technical evaluation of LBC systems – 
1. QC data sheet 
 
System X QC data 
 
This form should be completed for each run. 
 
Run date  Run 
number 
 Start time  
 
Finish time  No. samples processed  
 
 
 
 
 
 
 
 
 
 
 
Macroscopic assessment of slides.  (Please assess on overall 
appearance of run.  If individual cases differ significantly record in 
additional comments section.) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Details of any samples not processed* 
Amount of material (please circle one) 
 
Low Average High 
 
Distribution of material (circle yes or no and give brief details) 
 
Holes Yes / No 
Crescents Yes / No 
Peripheral rim Yes / No 
Other Yes / No 
Additional comments* 
Repeat preparations required Yes / No (please circle one) 
If yes, please state reason and give details* 
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1. QC data sheet (continued) 
 
 
 
 
 
 
 
    *If insufficient space please continue overleaf 
Supplemental processing required Yes / No (please circle one) 
If yes, please state reason and give details* 
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2. CEP technical evaluation of LBC systems – 
macroscopic/microscopic/reproducibility data sheet 
 
System X 
 
Run date  Run number  
 
Case 
number 
 
Repeat 
number 
 
 
Macroscopic assessment of cellularity (circle one choice)  
 
Low Average High 
 
Macroscopic assessment of evenness of distribution (lack of holes, 
crescents etc, if poor state type of unevenness) 
 
 Comment 
Good  Average Poor  
 
Microscopic assessment 
 
Cell numbers (circle one choice, perform cell count if appears <15000)  
 
<5000 cells 5000-15000 cells >15000 cells 
 
Quality of preparation (circle one choice for each, if a choice with an 
asterix is circled please specify the cause in the comments box 
 
     Comment 
Cell 
presentation 
Good Satisfactory Poor* 
Very 
poor* 
 
Cytolysis None Slight Some Marked  
Obscuring 
elements 
None Some Moderate* Marked*  
Cytoplasmic 
staining 
Good Satisfactory Poor* 
Very 
poor* 
 
Nuclear 
staining 
Good Satisfactory Poor* 
Very 
poor* 
 
3-
dimensionality 
Flat Slight Moderate Marked  
Cell drift Present Absent  
 
 
 
 161 
2. CEP technical evaluation of LBC systems – 
macroscopic/microscopic/reproducibility datasheet (continued) 
 
Repeat/supplemental processing 
 
   Details (if yes) 
Repeat processing 
required 
Yes No  
Supplemental processing 
required 
Yes No  
 
 
Cell types present (circle all seen) 
 
Superficials Intermediates Parabasal/basal 
Metaplastics Endocervicals Endometrials 
 
Dyskaryosis (state highest grade seen and circle amount) 
 
Grade  
Amount Scanty Some Many 
Specific 
type(s) if 
present 
Small cell Pale cell Bland cell 
Microbiopsy Other: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Comments: 
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3. System X error log 
  
Run date  Run number  
Error logged (include code) 
Remedial action (say whether engineer called or in-house solution) 
Outcome 
Downtime  
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Appendix G 
Sample Dilution Algorithm 
The unit‟s software uses an algorithm to adjust the amount of cells 
applied to the slide (cellularity) by varying the amount of water, GluCyte, 
and transfer volumes for each individual sample. This dilution process is 
based on an approximation of the number of cells starting in the 
pelletized sample. 
While the software determines the dilution and transfer volumes to arrive 
at a specific cellularity, it is instructional to examine an example 
calculation that does the reverse. The following example determines 
cellularity with assumed volumes as a way to illustrate the equations 
used in the algorithm. 
 
1. The volume of the cell pellet in the primary tube is determined by 
translating the pellet height found by the ultrasonic sensor to a volume 
based on the internal geometry of the tube. In our example assume this 
volume to be: 
V pellet = 100 ul  
 
2. Assume we know that a cell pellet after centrifugation has a 
concentration of: 
C pellet = 21,000 cells / ul 
 
3. The number of cells in the pellet is: 
N pellet = C pellet V pellet 
= (21,000 cells / ul) 100 ul 
= 21,00,000 cells 
 
4. Assume we add 200 ul of water to the tube: V water = 200 ul  
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5. The volume in the primary tube is now: 
V primary = V water  pellet =200 u  ul=300 ul  
 
6. Since we know the primary diluted volume in the tube and the 
number of cells in the tube we can calculate the diluted concentration in 
the primary tube: 
C primary = N pellet / V primary  
= 2,100,000 cells / 300 ul  
= 7000 cells / ul 
 
7. Assume we transfer 80 ml of fluid out of the primary tube to the 
secondary tube: 
V primary transfer = 80 ul  
 
8. As long as the solution in the primary tube is adequately mixed, the 
80 ml aspirated from the solution will have the same concentration as the 
rest of the solution. We therefore can determine the number of cells 
carried in the primary transfer volume to be: 
N primary transfer = C primary V primary transfer 
N primary transfer = 7000 ul x 80 ul = 560,000 cells 
 
9. Assume the volume of GluCyte dispensed into the secondary tube 
is:  
V GluCyte = 200 ul  
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10. Since the 80 ml of primary transfer solution is added to the 
secondary tube along with the GluCyte, the total volume of the secondary 
tube is now: 
V secondary =V GluCyte  primary transfer =200 ul  80 ul = 280 ul 
 
11. We know that the 80 ml of primary transfer solution carried 560,000 
cells, so we can calculate the resultant concentration in the secondary 
tube: 
C secondary = N primary transfer / V secondary  
= 560,000 cells / 280 ul  
=  2000 cells / ul 
 
12. Assume we transfer 40 ml of fluid from the secondary tube to the 
slide:  
V secondary transfer  = 40ml 
 
13. As long as the solution in the secondary tube is adequately mixed, 
the 40 ml aspirated from the secondary tube will have the same 
concentration as the rest of the fluid in the tube. We therefore can 
calculate the number of cells carried in the slide transfer volume: 
 
N slide = C secondary V secondary transfer  
= 2000 ml x 40 ul = 80,000 cells 
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14. Assume the unit is set up to dispense fluid to the slide in a 15 mm 
by 20 mm rectangle. This gives an area of: 
Area = 15 mm 20 mm= 300 mm2 
 
15. Knowing the number of cells and the deposit area the cellularity is 
found to be: 
Cellularity = N secondary transfer / Area  
= 80,000 cells / 300 mm2  
= 267 cells / mm2 
 
The above calculation can very precisely determine cellularity so long as 
the starting pellet volume and pellet concentration are known and the 
solutions in the primary and secondary tubes are well mixed. While this 
method produces very consistent cellularity, it is not exact due to sample 
to sample variations that can cause minor differences in the number of 
cells per slide. 
